Silvana Martino, D.O.
Curriculum Vitae
Page 1
SILVANA MARTINO, D.O., F.A.C.O.I.
CURRICULUM VITAE
OFFICE ADDRESS:
The Angeles Clinic And Research Institute
2001 Santa Monica Boulevard, Suite 560W
Santa Monica, California 90404
Telephone: (310) 582-7900
Facsimile: (310) 582-7918
11818 W ilshire Boulevard, Suite #200
Los Angeles, CA 90025
Telephone: (310) 231-2192
PERSONAL DATA:
Born - September 7, 1948, Italy.
Spouse – John R. Hill
EDUCATION:
1970
1973
B.S., Degree, W ayne State University, Detroit, MI.
D.O., Degree, Michigan State University College of Osteopathic Medicine, East Lansing, MI.
TRAINING:
1973 - 1974
1974 - 1977
1977 - 1979
Internship, Detroit Osteopathic Hospital, Detroit, MI.
Residency in Internal Medicine, Botsford Hospital, Farmington, MI.
Fellowship in Oncology, W ayne State University School of Medicine, Detroit, MI.
FACULTY APPOINTMENTS:
1979 - 1988
1988 - 1993
1999 - 2003
2003
2003
2004 -2011
2011
Assistant Professor, Department of Medicine, Division of Hematology and Oncology,
W ayne State University School of Medicine, Detroit, MI
Associate Professor, Department of Medicine, Division of Hematology and Oncology,
W ayne State University School of Medicine, Detroit, MI
Faculty, The John W . W ayne Cancer Institute
Adjunct Faculty, The John W . W ayne Cancer Institute
Clinical Associate Professor of Medicine, Keck School of Medicine, University of Southern
California, Los Angeles, CA
Director, Breast Cancer Program, The Angeles Clinic and Research Institute, Santa Monica, CA
Director, Breast Cancer Research and Education, The Angeles Clinic Foundation,
Santa Monica, CA
Silvana Martino, D.O.
Curriculum Vitae
Page 2
HOSPITAL OR OTHER PROFESSIONAL APPOINTMENTS:
1979 - 1993
1979 - 1993
1979 - 1983
1981 - 1986
1983 - 1993
1984 - 1985
1987 - 1993
1989 - 1992
1990 - 1992
1992 - 1993
1993 - 1997
1997 - 1999
1998 - 1999
1999 - Present
2000 - Present
2002 - Present
2002 - 2004
2003 – 2004
2003 - 2007
Full-time staff, Harper-Grace Hospitals, Detroit, MI
University Affiliate, Section of Oncology, Department of Medicine, Hutzel Hospital, Detroit, MI
Coordinator, Oncology Housestaff, Harper-Grace Hospitals, Detroit, MI
Clinical Advisor, Breast Cancer Prognostic Study, Michigan Cancer Foundation, Detroit, MI
University Affiliate, Department of Medicine, Detroit Receiving Hospital, Detroit, MI
Michigan Cancer Foundation Volunteer and Community Service Committee
Medical Director, Breast Cancer Prevention Program, W ayne State University and
Harper-Grace Hospital, Detroit MI
Adjunct Appointment Graduate Faculty Department of Medicine, W ayne State Univ, Det, MI
Service Chief, Hematology/Oncology Division, Section of Breast, Lung and Biologic Response
Modifiers, W ayne State University, Detroit, MI
Service Chief, Section of Breast Cancer, Hematology/Oncology Division, W ayne State
University, Detroit, MI
Medical Director, W estlake Comprehensive Breast Center, W estlake, CA
Medical Director, The Breast Center - Van Nuys, CA
Member Steering Committee for NCIC - CTR trial, PV. 1 Idoxifene
John W ayne Cancer Institute, Santa Monica, CA
Saint John’s Health Center, Santa Monica, CA
Santa Monica/UCLA Hospital, Santa Monica, CA
Century City Hospital, Century City, CA
Member, Infection Control Committee, Santa Monica/UCLA Hospital, Santa Monica, CA
Member, Cancer Committee, St. John’s Hospital, Santa Monica, CA
MAJOR PROFESSIONAL SOCIETIES:
American Osteopathic Association
American College of Osteopathic Internists
American Society of Clinical Oncology
Michigan Association of Osteopathic Physicians and Surgeons (until 1990)
Southwest Oncology Group
International Association for Breast Cancer Research
American Association for the Advancement of Sciences
American Society of Preventive Oncology
American Association For Cancer Research, Inc.
LICENSURE AND BOARD CERTIFICATION:
Licensure-States of Michigan, W est Virginia and California
American Osteopathic Board of Internal Medicine, 1984
American Osteopathic Board of Oncology, 1984
GOOD CLINICAL PRACTIVE (GCP) TRAINING:
NIH online training – Protecting Human Research Participants (07Aug2009)
Silvana Martino, D.O.
Curriculum Vitae
Page 3
HONORS AND AWARDS:
1992
1994
1996
1997
1997
1998
1998-2000
1998-2000
1999
1999
1999
2001-2005
2001
2002
2002
2003
2004
2005
Fellow, American College of Osteopathic Internists
Listed in The Best Doctors In America. W oodward/W hite Inc. Publishers
Listed in The Best Doctors in America: Pacific Region. W oodward/W hite Inc. Publishers
Phillips Medal of Public Service: Ohio University-COM
Certificate of Merit, American Cancer Society
Listed in The Best Doctors in America. W oodward/W hite Inc. Publishers, 4th Edition
Certificate of Merit, American Cancer Society
Listed in W ho’s W ho in Medicine and Healthcare
Listed in W ho’s W ho in America, Millenium Edition
Listed in W ho’s W ho in the W orld, Millenium Edition
Listed in W ho’s W ho in Science and Engineering, Millenium Edition
Listed in W ho’s W ho in America
Honorary Board Member, American Cancer Society, Greater Conejo Valley
Listed in Best Doctors in America. W oodward/W hite Inc. Publishers.
Listed in W ho’s W ho of American W omen
Listed in W ho’s W ho in Science and Engineering (7th Edition)
Listed in W ho’s W ho in Medicine and Healthcare (5th Edition)
3rd Prize Award for abstract, American College of Obstetricians and Gynecologists 53rd Annual
Clinical Mtg
2005
Listed in W ho’s W ho of American W omen: Silver Anniversary Edition
2006
Listed in W ho’s W ho in Medicine and Healthcare (6th Edition)
2006
Celebration of Excellence Award, The W ellness Community:Valley/Ventura
2007
Researcher of the Year award,The American College of Ostopathic Internists
2007-2009 Listed in America’s Top Oncologists by the Consumer’s Research Council of America
2009-2010 Listed in W ho’s W ho in Medicine & Healthcare (7th Edition)
2010-2011 Listed in W ho’s W ho in America
2010
Listed in W ho’s W ho, The Global Directory, Top Doctor
2010-2011 Listed in W ho’s W ho of American W omen
2011-2012 Listsed in W ho’s W ho in Medicine & Healthcare
2012
Listed in Southern California Super Doctors
SERVICE:
Journal/Editorial Activity:
Reviewer for Breast Cancer Research and Treatment
Reviewer for Journal of Clinical Oncology
OTHER PROFESSIONALLY RELATED SERVICE:
1981 - 1982
1980 - 1984
1982 - 1983
1983 - 1984
1984 - 1987
1984 - 1987
1984 - 1992
1989 - 1992
1991
Oncology Department Salary Committee, W ayne State University, Detroit, MI
Oncology Department Education Committee, W ayne State University, Detroit MI
Department of Medicine Housestaff Selection Committee
Human Sexuality Committee, W ayne State University, Detoit MI
Oncology Fellowship Committee, W ayne State University, Detroit MI
W ayne State Medical School Promotions Review Committee, Detroit MI
Human Investigation Committee, W ayne State University, Detroit MI
W ayne State Univ, Department of Medicine, Promotions & Tenure Committee, Detroit, MI
W ayne State Univ, Department of Medicine, Compensation Committee, Detroit MI
Silvana Martino, D.O.
Curriculum Vitae
Page 4
National and International Boards and Committees:
1981 - Present
1981 - 1996
1984 - 1986
1985 - 1992
1987 - 1992
1987 - Present
1989
1989 - Present
1990
1990 - 1991
1990 - 1992
1991 - Present
1992
1992 - 2000
1993
1994
1993 - 1994
1995 - 1998
1999 - 2002
2002 - 2006
2004 - 2006
SW OG Breast Committee
SW OG Breast Cancer W orking Group
Chairman: American College of Osteopathic Internists, Hematology and Oncology
Section
Consultant: American Osteopathic Board of Internal Medicine, Subspecialty of
Oncology
Co-Chairman: SW OG Cancer Control Research Committee
SW OG Executive Committee of the Cancer Control Research Committee
National Cancer Institute ad hoc Grant Review Committee Minority Based Community
Clinical Oncology Program, March 14-16, 1989
SW OG Cancer Control Liaison to Breast Committee
Co-Chair, National Cancer Institute Grant Review Committee for Community Clinical
Oncology Program, November 28-30, 1990.
Program Committee for the American College of Osteopathic Internists Convention and
Scientific Seminar.
Member SW OG Minority Research Subcommittee
Advisory Board; SW OG Committee on W omen's Health and Special Populations
Chair - National Cancer Institute Grant Review Committee, RO1, Breast Cancer in the
Elderly, February 17-18, 1992.
Chairman; SW OG Breast Committee.
National Cancer Institute Review Committee for RFA CA-93-33
NCI - Review Committee for University of Pennsylvania Cancer Center Core Grant
Board of Scientific Advisors: International Breast Cancer Research Foundation, Inc.
SW OG Data and Safety Montoring Committee
Reviewer for The Susan G. Komen Breast Cancer Foundation National Grant
Program
Member, Oncology Drugs Advisory Committee (ODAC), Food & Drug Administration
Chairman, Oncology Drugs Advisory Committee (ODAC), Food & Drug Administration
State and Local Boards and Committees:
1980 - 1990
1984 - 1990
1987 - 1988
1987 - 1993
1994 - 1995
1995 - 1997
1995 - 1997
1995 - 1997
1995 - 1998
1996 - 1999
1996 - Present
2007 - Present
2008 - Present
Harper Hospital Emergency Room Committee (Detroit, Michigan)
DMCIOAD Board of Trustees (Detroit, Michigan)
Advisory Committee for community Health Programs, Harper-Grace Hospitals
(Detroit, Michigan)
Cancer Committee for Harper Hospital (Detroit, Michigan)
American Cancer Society - Board of Directors, Ventura County
Cancer Committee for W estlake Medical Center
Insitutional Review Board for W estlake Medical Center
Cancer Committee for Los Robles Regional Medical Center
American Cancer Society/Greater Conjeo Valley Unit, V.P. Volunteer Development
W ellness Community Valley/Ventura Board of Directors
W ellness Community Valley/Ventura member of Professional Advisory Board
Persian American Cancer Institute (PACI)
California Breast Cancer Research Program, “Intraductal Therapy of DCIS: A
Presurgery Study”, Data Safety Monitoring Board (Santa Monica, CA)
TEACHING:
Wayne State University: 1979 - 1993 - Medical Oncology, General Medicine, and Physical Diagnosis.
Courses Taught at Wayne State University:
Silvana Martino, D.O.
Curriculum Vitae
Page 5
Undergraduate:
Prevention and Cancer Control, W SU, Dept. of Biological Sciences, April 1987 and 1988.
Teaching (continued):
Graduate:
Diet in Breast Cancer Prevention, W SU, Dept. of Metabolism and Nutrition, April, 1987.
Graduate Professional School:
1.
"Sexual Dysfunction of Breast Cancer", W SU Medical School year 2 class. (Yearly 1984-1990).
2.
"Breast Cancer", Oncology Section of the Disease Processes and Therapeutic Course for the Doctor of
Pharmacy Candidates W SU, October 1985 and February 1988.
3.
"Breast Cancer", Diet and Nutrition in Breast Cancer. Cancer Biology Ph.D. Program Course, W ayne State
University, November 25, 1991.
4.
"Breast Cancer", Chemotherapy. Cancer Biology Ph.D. Program Course, W ayne State University,
December 2, 1991.
5.
"Sexual Dysfunction of Breast Cancer", W SU Medical School, Year 2 class, September 1992.
6.
"Chemotherapy and Dietary Prevention of Breast Cancer", Cancer Control Course (CB.725), W ayne State
University, January 1993.
7.
The John W ayne Cancer Institute Clinical rotation for: General Surgical Oncology Fellows and Breast
Surgical Oncology fellows, 1999 – On.
8.
University of Southern California (USC): Clinical rotation for: Medical Oncology Fellows, 2003 - 2008
Essays/Theses/Dissertations Directed:
1979 – 1993 Member of Dissertation Committee for Diane Lancaster, Ph.D. Candidate, Department of Nursing.
Other:
1979 – 1993 Rounding in Internal Medicine, Medical Oncology and Physical Diagnosis at Harper
Hospital, Detroit, Michigan.
GRANT SUPPORT:
Funded:
1982 – 1984
Schering Corporation Study C82-034-02 Phase II Trial of SCH-30500 Interferon Alpha2 in
Carcinoma of the Breast, Principal Investigator.
1985 – 1987
Phase I Study of Recombinant Beta Interferon (IFN-beta Ser-17), Ceta-Shell Corporation.
Co-Investigator.
1986 – 1989
Upjohn Company, R-9134, Phase II Study of Menogaril as First Line Therapy in Advanced Breast
Cancer - ($40,000), Principal Investigator.
Silvana Martino, D.O.
Curriculum Vitae
Page 6
1987
TAP Pharmaceutical, Leuprolide vs. Leuprolide + Tamoxifen in Premenopausal Breast
Patients with Metastatic Disease - ($10,000), Co-Investigator.
Cancer
987
W ayne State University Research Stimulation Fund, Prolactin Changes in High Risk Breast
Cancer Patients on Low Fat Diet - ($10,000), Principal Investigator.
1987 – 1989
RO1 (NCI) Breast Cancer Cell Kinetics - ($10,000), Co-Investigator.
1987 – 1988
Breast Cancer Prevention Program, Marilyn Smith Breast Cancer Research Fund. Private
Donation -($100,000), Principal Investigator.
1989
Breast Cancer Prevention Program, Florence L. Graham, Private Donation, ($134,000), Principal
Investigator.
1989
Breast Cancer Prevention Program, Michigan Ladies Auxilliary Donation, ($7,945), Principal
Investigator.
1989 – 1990
Bio Science Phase II Evaluation of W R 2721 & Platinum for Refractory Metastatic Breast Cancer,
($14,000), Co-Investigator.
1988 – 1992
NCI, Low-Fat Diet in Stage II Breast Cancer-Randomized Study. ($680,569); Co-Investigator;
(Sub-contract).
1991 – 1992
ACS, Institutional Application Clinical Oncology Fellowship ($110,000), Co-Investigator, 5% effort.
1991 – 1999
NCI-NSABP - A Clinical Trial to Determine the W orth of Tamoxifen for Preventing Breast Cancer
(sub-contract) $1300\patient.
1993 – 1993
NCI, SW OG Breast Cancer Committee ($15,567), Principal Investigator.
1993 – 1996
NCI - W omen's Intervention Nutritional Study (W INS) (sub-contract) $1,700\patient.
1994 – 1994
NCI, SW OG Breast Cancer Committee ($16,525), Principal Investigator.
1995 – 1995
NCI, SW OG Breast Cancer Committee ($16,328), Principal Investigator.
1996 – 1996
NCI, SW OG Breast Cancer Committee ($16,574), Principal Investigator.
1997 – 1997
NCI, SW OG Breast Cancer Committee ($16,894), Principal Investigator.
1998 – 1998
NCI, SW OG Breast Cancer Committee ($9,905), Principal Investigator.
1999 – 1999
NCI, SW OG Breast Cancer Committee ($9,024), Principal Investigator.
1999 – 2001
RPR, Neoadjuvant Epirubicin and Taxotere weekly for Breast Cancer with biological correlates
(Per patient payment).
1999 – 2001
Pharmacia, Neoadjuvant Epirubicin and Taxotere weekly for Breast Cancer with biological
correlates (Per patient payment).
1999– Present NCI, SW OG and CTSU Trials (Per patient payment).
2000 – 2000
NCI, SW OG Breast Cancer Committee ($15,619), Principal Investigator.
2000 – 2003
NCI, Pharmacology of Anticancer Drugs in Advanced age; [Derek Raghavan, PI for SW OG,
($1,212,304)], Co-Investigator 2% salary.
June
American BioScience, Inc., A Controlled Randomized Phase III, Multicenter, Open Label Study of
ABI-007 (A Cremophor®-Free, Protein Stabilized, Nanoparticle Paclitaxel) and Taxol® in Patients
W ith Metastatic Breast Cancer (Per patient payment).
2001
Silvana Martino, D.O.
Curriculum Vitae
Page 7
August 2002 Novartis Pharmaceuticals, An Open-Label, Randomized, Multicenter Study to Evauate the Use of
Zolecronic Acid in the Prevention of Cancer Treatment-related Bone Loss in Postmenopausal
W omen with ER+ and/or PR+ Breast Cancer Receiving Letrozole as Adjuvant Therapy (Per
patient payment).
2003 – 2004 Trio Clinical Research, LLC, An Open-Label, Phase II Trial of the Immunological Response Rate,
Safety, and Tolerability of THERATOPE Vaccine in Subjects with Metastatic Breast Cancer
Undergoing Treatment with Aromatase Inhibitors or Faslodex (Per patient payment).
2007
PFIZER Clinical Protocol, A Phase 3 Study of SOU11248 in Combination with Paclitaxel versus
Bevacizumab with Paclitaxel in the First-line Advanced Disease Setting in Patients having Breast
Cancer. (per patient payment).
2008 a
PFIZER Clinical protocol, Comparison of Sutent and Taxol versus Avastin and Taxol as first line
Therapy in Metastatic Breast Cancer. (per patient payment)
2009a
NOVARTIS Clinical protocol, Bollerro trial in metastatic breast cancer. (per patient payment).
2010
CELLDEX Clinical protocol, CDX 011-03 trial in metastatic breast cancer. (per patient payment).
2011
GENENTECK and HOFFMAN-La ROCHE ltd, Emilia trial in metastatc breast cancer. (per patient
payment).
2011
AMGEN, D-Care clinical trial in adjuvant breast cancer. (per patient payment).
2011
NATIONAL INSTITUTES OF HEALTH, Menopause and related health effect of (Neo) adjuvant
Therapy for breast cancer. (Sub PI ).
PUBLICATIONS:
Original Observations in Journals:
1. Martino S, Samal BA, Al-Sarraf M. Phase II study of 5-fluorouracil and adriamycin in transitional cell
carcinoma of the urinary tract. Cancer Treat Rep., 64(1):161-3, 1980.
2. Samal BA, Brooks SC, Cummings G, Franco L, Hire EA, Martino S, Singhakowinta A, Vaitkevicius VK.
Estrogen receptors and responsiveness of advanced breast cancer to chemotherapy. Cancer. 15;46 (12
Suppl):2925-2927, December 1980
3. Martino S, Samal BA, Singhakowinta A. PCNU in advanced breast cancer. Cancer Treatment Rep. 1983
March; 67(3):305-6.
4. Ownby H, Martino S, Russo J, Roi L, Brennan MF. Interrupted Pregnancy as an Indicator of Prognosis in
Primary Breast Cancer. Breast Cancer Res Treat. 3(4):339-44,1983.
5. Martino S, Samal BA, Singhakowinta A, Yoshida S, Mackenzie M, Jain J, Vaitkevicius VK. A Phase II Study
of Cis-Diamminedichloroplatinum II for Advanced Breast Cancer Utilizing Two Dose Schedules. J Cancer
Res Clinical Oncology, 108(3):354-6, 1984.
6. Muss HB, Kemp RA, Martino S, Rudnick SA, Greiner J, Cooper MR, Decker D, Grunberg SM, Jackson DV,
and Richards F 2d. A Phase II Study of Recombinant Alpha Interferon in Patients with Recurrent or
Metastatic Breast Cancer. JCO 2(9):1012-16, 1984.
Silvana Martino, D.O.
Curriculum Vitae
Page 8
Original Observations in Journals (continued):
7. Martino S, Ratanatharathorn V, Karanes C, Samal BA, Sohn YH, Rudnick SA. Reversible Arrhythmias
Observed in Patients Treated with Recombinant Alpha 2 Interferon. J Cancer Res Clinical Oncology,
113(4):376-8, 1987.
8. Martino S, Decker DA, Hines HE, Kresge C. Phase II Evaluation of Aclacinomycin-A in Ovarian Carcinoma.
Invest New Drugs, 5(4):373-374, December 1987.
9. Ajluni S, Martino S, Singhakowinta A, Samal BA, Decker DA. Characteristics of Cranial Nerve Palsies
Due to Osseous Metastases in Metastatic Breast Cancer. Department of Medicine Bulletin, 2(1):23-26,
1988.
10. Apel J, Singhakowinta A, Martino S, Samal BA, Bergsman K, Vaitkevicius V. Repeat Combination
Chemotherapy Following Adjuvant Use in Advanced Breast Cancer. Department of Medicine Bulletin,
2(1):46-51, 1988.
11. Martino S, Ratanatharathorn V, Samal BA, Singhakowinta A. Treatment of Metastatic Breast Cancer with
AZQ: A Phase II Trial. Cancer Invest, 6(3):289-91, 1988.
12. Gala R, Martino S, W iejowski SA, Kresge CL, Alonso MDM. Serum Interleukin 2 (IL-2) Levels and Prolactin
Bioactive/Radio-Immunoassay Ratios of W omen at Risk for Breast Cancer. Eur J Cancer Clin Oncology,
25(11):1603-5, November 1989.
13. Flaherty LE, Redman BG, Chabot GG, Martino S, Gualdoni SM, Heilbrun LK, Valdivieso M, and Bradley EC.
A Phase I-II Study of Dacarbazine in Combination W ith Outpatient Interleukin-2 in Metastatic Malignant
Melanoma. Cancer, 65(11):2471-2477, June 1, 1990.
14. Redman BG, Flaherty LE, Chou T, Al-Katib A, Kraut MJ, Martino S, Chen B, Kaplan J, Valdivieso M.
A Phase I Trial of Recombinant Interleukin-2 Combined W ith Recombinant Interferon-Gamma in Patients
W ith Cancer. J Clinical Oncology, 8:1269-1276, 1990.
15. Martino S, Samal B, Redman B, Flaherty L, Kraut M, Simon M, Valdivieso M. Phase II Study of
Deoxydoxorubicin in Previously Untreated Breast Cancer. Breast Cancer Res Treat,17(2):139-143,
December 1990.
16. Djuric Z., Heilbrun LK, Reading BA, Boomer A, Valeriote FA, Martino S. Effects of a Low-Fat Diet on
Oxidative DNA Damage Levels in Human Peripheral Nucleated Blood Cells. J National Cancer Inst.,
83(11):766-769, June 5, 1991.
17. Cowan, J.D., Neidhart, J., McClure, S., Coltman Jr., C.A., Gumbart, C., Martino, S., Hutchins, L.F.,
Stephens, R.L., Vaughan, C.B., Osborne, C.K. Randomized Trial of Doxorubicin, Bisantrene, and
Mitoxantrone in Advanced Breast Cancer: A Southwest Oncology Group Study. J National Cancer Inst,
83(15):1077-1084, August 7, 1991.
18. Flaherty, L., W ozniak, A., Redman, B., Kraut, M., Martino, S., Heilbrun, L, Valdivieso, M. 5-FU,
Etoposide and Cisplatin in the Management of Metastatic Non-Small Cell Lung Cancer.
68(5):944-947, September 1991.
Cancer,
19. Simon, M.S., Schwartz, A.G., Martino, S., Swanson, G.M. Trends in the Diagnosis of Insitu Breast Cancer
in the Detroit Metropolitan Area, 1973-1987. Cancer, 69(2):466-469, January 15, 1992.
20. Simon, M.S., McKnight, E., Schwartz, A., Martino, S., Swanson, G.M. Racial 1991, Differences in Cancer of
the 1991, Male Breast - 15 year experience in the Detroit Metropolitan Area. Breast Cancer Res Treat,
21(1):55-62, 1992.
21. Redman, B., Flaherty, L., Chou, T.H., Kruat, M., Martino, S., Simon, M., Valdivieso, M., Groves, E. Phase I
trial of recombinant macrophage colony stimulating factor. J. Immunother 1992 Jul;12(1):50-54, July 1992.
Silvana Martino, D.O.
Curriculum Vitae
Page 9
Original Observations in Journals (continued):
22. Redman, B.G., Flaherty, L., Martino, S., Kraut, M., W isniewski, C., Valdivieso, M., Bander, J.J. Effect of
Calcium Replacement on the Hemodynamic Changes Associated W ith High Dose Interleukin-2 Therapy.
Am J Clin Onc 1992 Aug;15(4):340-3.
23. Kasim, S.E., Martino, S., Paik-Nyon, K., Khilinani, S., Boomer, A., Depper, J., Reading, B.A., Heilbrun, L.K.
Dietary and anthropometric determinants of plasma lipoproteins during a long-term low-fat diet in healthy
women. Amer J of Clin Nutri 1993 Feb;57(2):146-53.
24. Flaherty, L.E., Robinson, W ., Redman, B.G., Gonzalez, R., Martino, S., Kraut, M.J., Valdivieso, M., Rudolph,
A.R. A Phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin-2
in metastatic malignant melanoma. Cancer 1993 Jun 1;71(11):3520-5.
25. Simon, M.S., Hoff, M., Hussein, M., Martino, S., W alt, A. An evaluation of clinical follow-up in women with
early stage breast cancer among physician members of the American Society of Clinical Oncology. Breast
Cancer Res Treat1993 Sept;27(3):211-9.
26. Simon, M.S., Lemanne, D, Schwartz, A.G., Martino, S., Swanson, M. Recent Trends in the Incidence of In
Situ and Invasive Breast Cancer in the Detroit Metropolitan Area (1975-1988). Cancer1993 Feb 1;71(3):76974.
27. Chlebowski, R.T., Blackburn, G.L., Buzzard, I.M., Rose, D.P., Martino, S., Khandekar, J.D., York, M.R.,
Jeffery, R.W ., Elashoff, R.M., W ynder, E.L. Adherence to a dietary fat intake reduction program in
postmenopausal women receiving therapy for early breast cancer. Journal of Clinical Oncology,11
(11):2072-80, 1993.
28. Ensley J, W eaver D, Benitez P, An T, Maciorowski Z, Alonso M, Kukuruga M, Martino S. Dietary Modulation
of Abnormal DNA Histograms From Breast Aspirates of Patients at High Risk for Developing Breast Cancer.
Cancer Molecular Biology 1994 Jan-Feb;1:45-51.
29. Fabian CJ, Kimler BF, McKittrick R, Park CH, Lin F, Krishnan L, Jewell W R, Osborne CK, Martino S,
Hutchins LF, Leong LA, Green S. Recruitment with high physiologic doses of estradiol preceding
chemotherapy: flow cytometric and therapeutic results in women with locally advanced breast cancer.
Cancer Res 1994 Oct 15;54(20):5257-62.
30. Ravdin PM, Green S, Doroshow JH, Martino S. Phase II trial of piroxantrone in metastatic breast cancer. A
Southwest Oncology Group Study. Investi New Drugs 1994;12(4): 333-6.
31. Budd GT, Green S, O'Bryan RM, Martino S, Abeloff MD, Rinehart JJ, Hahn R, Harris J, Tormey D,
O'Sullivan J, Osborne CK. Short Course FAC-M vs. 1 year of CMFVP in Node-Positive, Hormone-Receptor
Negative Breast Cancer: an Intergroup Study. J Clin Oncol 1995 April;13(4)831-9.
32. Djuric Z, Heilbrun LK, Simon MS, Smith D, Luongo DA, LoRusso PM, Martino S. Levels of 5Hydroxymethyl-2'-Deoxyuridine in DNA from Blood as a Marker of Breast Cancer. Cancer 1996 Feb
15;77(4):691-6.
33. Albain KS, Green SR, Lichter AS, Hutchins LF, W ood, W C Henderson IC, Ingle JN, O'Sullivan J, Osborne
CK, Martino S. Influence of Patient Characteristics, Socioeconomic Factors, Geography and Systemic Risk
on the Use of Breast Sparing Treatment in W omen Enrolled in Adjuvant Breast Cancer Studies: An
Analysis of Two Intergroup Trials. J Clin Oncol 1996;14(11):3009-17.
34. Simon MS, Heilbrum LK, Boomer A, Kresge C, Depper J, Kim PN, Valeriote F, Martino S. A Randomized
Trial of a Low-Fat Dietary Intervention in W omen at High Risk for Breast Cancer. Nutr Cancer
1997;27(2),136-42.
Silvana Martino, D.O.
Curriculum Vitae
Page 10
Original Observations in Journals (continued):
35. Russell CA, Green SJ, O'Sullivan J, Hynes HE, Budd GT, Congdon JE, Martino S, Osborne CK. Megestrol
Acetate and Aminoglutethimide/ Hydrocortisone in Sequence or in Combination as Second-Line Endocrine
Therapy of Estrogen Receptor Positive Metastatic Breast Cancer: A Southwest Oncology Group Phase III
Trial. J Clin Oncol 1997;15(7):2494-2501.
36. Elledge RM, Green S, Howes L, Clark GM, Berardo M, Allred DC, Pugh R, Ciocca D, Ravdin P, O'Sullivan J,
Rivkin S, Martino S, Osborne CK. bc1-2, p53, and Response to Tamoxifen in Estrogen Receptor-Positive
Metastatic Breast Cancer: A Southwest Oncology Group Study. J Clin Oncol 1997;15(5):1916-22.
37. Ramnath N, LoRusso P, Simon M, Martino S. Phase II Evaluation of Cisplatin and W R2721 for Refractory
Metastatic Breast Cancer. Am J Clin Oncol 1997 Aug;20(4):368-72.
38. Silverstein MJ, Lagios MD, Martino S, Lewinsky BS, Craig PH, Beron P, Gamagami P, W aisman JR.
Outcome After Invasive Local Recurrence in Patients with Ductal Carcinoma in Situ of the Breast.
J Clin Oncol 1998 Apr;16(4)1367-73.
39. Taylor CW , Green S, Dalton W S, Martino S, Rector D, Ingle JN, Robert N, Budd GT, Paradelo JC, Natale
RB, Bearden JD, Mailliard JA, Osborne CK. A Multi-Center Randomized Clinical Trial Of Goserelin vs.
Surgical Ovariectomy In Pre-Menopausal Patients W ith Receptor Positive Metastatic Breast Cancer: An
Intergroup Study. J Clin Oncol 1998 March; 16(3)994-99.
40. Elledge RM, Green S, Ciocca D, Pugh R, Clark GM, Hill J, Ravdin P, O'Sullivan J, Martino S, Osborne CK.
HER-2 expression and response to tamoxifen in estrogen recetor-positive breast cancer: A Southwest
Oncology Group Study. Clin Cancer Res 1998 Jan;4(1)7-12.
41. Djuric Z, Depper JB, Uhley V, Smith D, Lababidi S, Martino S, Heilbrun LK. Oxidative DNA damage levels in
blood from women at high risk for breast center are associated with dietary intake of meats, fruits and
vegetables. J Am Diet Assoc May 1998;98(5)524-28.
42. Ciocca D, Green SJ, Elledge R, Clark G, Pugh R, Ravdin P, Lew D, Martino S, Osborne CK. Heat shock
proteins, Hsp27 and Hsp 70: Lack of correlation with response to tamoxifen and clinical course of disease in
estrogen receptor-positive metastatic breast cancer: A Southwest Oncology Group Study. Clinical Cancer
Research 1998 May;4(5)1263-1266.
43. Early Breast Cancer trialist Collab. Group (Martino S for SW OG). Tamoxifen for early breast cancer: an
overview of the randomized trials: Lancet 1998 May; 351(9114)1451-67.
44. Geyer CE Jr, Green S, Moinpour CM, Sullivan J, Goodwin DK, Canfield VA, Meyers FJ, Martino S.
Expanded phase II trial of paclitaxel in metastatic breast cancer: A Southwest Oncology Group Study.
Breast Cancer Res Treat 1998 Sept;51(2)169-81.
45. Early Breast Cancer Trialist, Collabarative. Group, (S. Martino, for SW OG) Polychemotherapy for early
breast cancer: an overview of the randomized trials: Lancet 1998 Sept;352(9132):930-42.
46. Silverstein MJ, Lagios MD, Groshen S, W aisman JR, Lewinsky BS, Martino S, Gamagami P, Colburn W J.
The influence of margin width on local control of ductal carcinoma in situ of the breast. N Engl J Med 1999
May;340(19):1455-61.
47. Ellis GK, Green S, Livingston RB, Pierce HI, Paradelo JC, Taylor SA, Martino S. Neo-FAC" (5-fluorouracil,
doxorubicin and cyclophosphamide) for poor prognosis stage IV breast cancer: A Southwest Oncology
Group Phase II Study. Am J Clin Oncol 1999 Oct;22(5):446-49.
48. Gale RP, Park RE, Dubois R, Bitran JD, Buzdar A, Hortobagyi G, Jones SE, Lazar G, Spitzer G, Swain SM,
Vaughn CB, Vogel C, Martino S. Delphi-panel analysis of appropriateness of high-dose chemotherapy and
blood cell or bone marrow autotransplants in women with breast cancer. Clinical Transplant 2000
Feb;14(1):32-41.
Silvana Martino, D.O.
Curriculum Vitae
Page 11
Original Observations in Journals (continued)
49. Elledge RM, Green S, Pugh R, D. Allred C, Clark GM, Hill J, Ravdin P, Martino S, Osborne CK. ER and
PgR Ligand binding assay compared with ER, PgR and pS2 by immunohistochemistry in predicting
response to tamoxifen in metastatic breast cancer: A Southwest Oncology Group Study. Int J Cancer 2000
March 20;89((2);111-17.
50. Stadtmauer EA, Neill, AO, Goldstein LJ, Crilley PA, Mangan, KF, Ingle JN, Luger SM, Klumpp TR, Brodsky
I, Litzow MR, Martino S, Lazarus HM, Erban JK, Sickles C, Glick JH. Conventional dose chemotherapy
compared to high dose chemotherapy with autologous stem cell transplantation in the management of
responding metastatic breast cancer: The Philadelphia Intergroup Trial (PBT-1). N Engl J Med 2000 Apr
13;342(15):1069-76.
51. Early Breast Cancer Trialists Collab. Group, (S. Martino, for SW OG) Favorable and unfavorable effects on
long–term survival of radiotherapy for early breast cancer: an overview of the randomized trials, The Lancet
2000 May 20; 355(9712):1757-70.
52. Page D, Gray R, Allred DC, Dressler L, Hatfield A, Martino S, Robert N, W ood W . Prediction of node
negative C Outcome by histologic grading and S-phase analysis by flow cytometry: An ECOG study (2192).
Am J Clin Oncol 2001 Feb;24 (1):10-18.
53. Roche PC, Suman VJ, Jenkins RB, Davidson NE, Martino S, Kaufman PA, Addo FK, Murphy B, Ingle JN,
Perez EA. Concordance Between Local and Central Laboratory HER2 Testing in the Breast Intergroup Trial
N9831. J Natl Cancer Inst 2002 June 5;94(11):855–57.
54. Rivkin SE, Green SJ, Lew D, Costanzi JJ, Athens JW , Osborne CK, Vaughn CB, Martino S. Adjuvant
Chemotherapy with Cyclophosphamide, Methotrexate, and 5-Fluorouracil, Vincristine, and Prednisone
compared with Single-Agent L-Phenyulalanine Mustard for Patients with Operable Breast Cancer and
Positive Auxillary Lymph Nodes. Cancer. 87(1):21-9, January 1, 2003.
55. Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein L, Martino S, Ingle JN, Cooper MR, Hayes
DF, Tkaczuk KH, Fleming G, Holland JF, Duggan DB, Carpenter JT, Frei III E, Schlinsky RL, W ood W C.
Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an
adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.
J Clin Oncol 2003
March 15;21(6)976-83.
56. Ellerbroek N, Martino S, Mautner B, Tao ML, Rose C, Botnick L. Breast-Conserving Therapy with Adjuvant
Paclitaxel and Radiation Therapy: Feasibility of Concurrent Treatment. The Breast Journal, 2003, 9(2)74-8.
57. Citron ML, Berry DA, Cirrincione C, Hudis C, W iner EP, Gradishar W J, Davidson NE, Martino S, Livingston
R, Ingle JN, Perez EA, Carpenter J, Hurd D, Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Schilsky
RL, Muss HB, and Norton L. Randomized trial of dose dense vs. conventionally scheduled and sequential
vs. concurrent combination chemotherapy as post-operative adjuvant treatment of node-positive primary
breast cancer: first report of intergroup trial C9741/Cancer and Leukemia Group B trial 9741. J Clin Oncol
2003 April 15;21(8)1431-1439.
58. Sledge G, Neuberg D, Bernardo P, Ingle J, Martino S, Rowinsky E, W ood W . Phase III Trial of doxorubicin,
paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic
breast cancer: An intergroup trial (E1193). J Clin Oncol 2003 February 15;21(4) 588-592.
59. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE,
Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater
JL. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for earlystage breast cancer. New Engl J Med 2003 Nov 6;349(19):1793-1802.
60. Martino S, Costantino J, Secrest R, McNabb M, Bryant K, Powles T, Mershon J. The role of selective
estrogen receptor modulators in the prevention of breast cancer: Comparison of the clinical trials. The
Oncologist 2004; 9:116-125.
Silvana Martino, D.O.
Curriculum Vitae
Page 12
Original Observations in Journals (continued):
61. Lyman GH, Green S, Ravdin PM, Geyer CE Jr, Russell CA, Balcerzak SP, Budd GT, Martino S. A
Southwest Oncology Group randomized phase II study of doxorubicin and paclitaxel as frontline
chemotherapy for women with metastatic breast cancer. Breast Cancer Research and Treatment 2004;
85:143-150.
62. Perez EA, Suman VJ, Davidson NE, Kaufman PA, Martino S, Ingle JN, Rodeheffer RJ, Gersh BJ, Jaffe AS.
Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast
cancer in the NCCTG N9831 intergroup adjuvant trial. Journal of Clinical Oncology 2004; 22(18):37003704.
63. Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon J, Disch D, Secrest RJ, Cummings SR.
Continuing outcomes relevant to Evista: Breast cancer incidence in postmenopausal osteoporotic women in
a randomized trial of Raloxifene. Journal of the National Cancer Institute 2004; 96(23):1751-1761.
64. Arpino G, Green SJ, Allred DC, Lew D, Martino S, Osborne CK, Elledge RM. HER-2 amplification, HER-1
expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: A Southwest
Oncology Group Study. Clinical Cancer Research 2004; 10:5670-5676.
65. Hughes LL, Gray RJ, Solin LJ, Robert NJ, Robert, NJ, Martino S, Tripathy D, Ingle JN, W ood W C for
ECOG, SW OG, CALGB and NCCTG. Efficacy of radiotherapy for ovarian ablation: Results of a breast
intergroup study. Cancer 2004; 101(5):969-972.
66. Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon J, Disch D, Secrest RJ, Cummings SR.
RESPONSE – Correspondence: Yalcin B, Buyukcelik, Yalcin S, et. al Re:Continuing outcomes relevant to
Evista: Breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of Raloxifene.
Journal of the National Cancer Institute 2005; 97(7):542-543.
67. Martino S, Disch D, Dowsett SA, Keech CA, Mershon JL. Safety assessment of Raloxifene over eight
years in a clinical trial setting. Current Medical Research and Opinion 2005; 21(9):1441-1452.
68. Davidson NE, O’Neill AM, Vukor AM, Osborne CK, Martino S, W hite DR, Abeloff MD. Chemoendocrine
therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive
breast cancer: Results from INT 0101 (E5188). Journal of Clinical Oncology 2005; 23(25):5973-5982.
69. W helan T, Goss P, Ingle J, Pater J, Dongsheng T, Pritchard K, Liu S, Shepherd L, Palmer M, Tu D, Robert
N, Martino S, Muss H. Assessment of quality of life in MA.17: A randomized placebo-controlled trial of
letrozole after 5 years of tamoxifen in postmenopausal women. Journal of Clinical Oncology 2005; 23(28):
6931-6940.
70. Goss PE, Ingle JN, Martino S, Robert NJ, Hyman B, Piccart MJ, Castiglione M, Dongsheng T, Shepherd
LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ,
Pater JL. Letrozole following taxomifen as extended adjuvant therapy in receptor positive breast cancer:
NCIC CTG MA.17. J Natl Cancer Inst 2005; 97(17):1262-1271.
71. Romond, EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, Tan-Chiu E, Martino S, Paik S,
Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW , Yothers G,
Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle W L, Klein PM, Ingle JN, W olmark N. Improved
outcome with the addition of adjuvant trastuzumab to adjuvant chemotherapy in her2-positive breast cancer
combined anlysis of NSABP B-31 and NCCTG N9831. New England Journal of Medicine 2005; 353:16731684
72. Hutchins LF, Green SJ, Ravdin PM, Lew D, Martino S, Abeloff M, Lyss AP, Allred C, Rivkin SE, Osborne
CK. Randomized controlled trial of CMF versus CAF with and without Tamoxifen for high-risk,
node-negative breast cancer: Treatment results of intergroup protocol INT-0102. J Clin Oncol
2005;23(33):8313-8321.
Silvana Martino, D.O.
Curriculum Vitae
Page 13
Original Observations in Journals (continued):
73. Unger JM, Coltman Jr CA, Crowley Jj, Hutchins LF, Martino S, Livingston RB, Macdonald JS, Blanke CD,
Gandara DR, Crwaford ED, Albain KS. Impact of the Year 2000 Medicare policy change on older patient
enrollment to cancer clinical trials. J Clin Oncol 2005;24(1):141-144.
74. Berry DA, Cirrincione C, Henderson IC, Citron ML, Budman DR, Goldstein L, Martino S, Perez EA, Muss
HB, Norton L, Hudis C, W iner EP. Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for
Patients W ith Node-Positive Breast Cancer. JAMA 2006;295(14):1658-1667.
75. Perez EA, Suman VJ, Davidson NE, Martino S, Kaufman PA, Lingle W L, Flynn PJ, Ingle JN, Visscher D,
Jenkins RB. HER2 testing by local, central and reference laboratories in 1823 specimens from the NCCTG
N9831 Intergroup Adjuvant Trial. J Clin Oncol 2006; 24(19):3032-3038.
76. Perez EA, Josse RG, Pritchard KI, Ingle JN, Martino S, Findlay BP, Shenkier TN, Tozer RG, Palmer MJ,
Shepherd LE, Liu SF, TU D, Goss PE. Effect of Letrozole versus Placebo on Bone Mineral Density in
W omen with Primary Breast Cancer Completing Five or More years of Adjuvant Tamoxifen: A Companion
Study to NCIC CTG MA.17. J Clin Oncol 2006; 24(22):3629-3635.
77. Ingle JN, Tu D, Pater JL, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Shepherd LE,
Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams J, Cameron DA, Palmer MJ, Goss
PE. Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended
adjuvant therapy trial. Breast Cancer Res Treat 2006;99(3):295-300
78. Lippman ME, Cummings SR, Kisch DP, Mershon JL, Dowsett SA, Cauley JA, Martino S. Effect of
raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis
categorized by breast cancer risk. Clin Cancer Res 2006;12(17):5242-5247
79. Umetani N, Giuliano AE, Hiramatsu S, Amersi F, Nakagawa T, Martino S, Hoon DS. Prediction of Lymph
Node Metastases of Breast Cancer by Inegrity of Free Circulating DNA in Serum. J Clin Oncol.
2006;24(26):4270-4276.
80. Moore HC, Green SJ, Gralow JR, Bearman SI, Lew D, Barlow W E, Hudis C, W olff AC, Ingle JN, Chew HK,
Elias AD, Livingston RB, Martino S; Southwest Oncology Group/Intergroup Study 9623. Intensive dosedense compared with high-dose adjuvant chemotherapy for high-risk operable breast cancer: Southwest
Oncology Group/Intergroup study 9623. J Clin Oncol. 2007, 25(13):1677-82
81. Linden HM, Haskell CM, Green SJ, Osborne CK, Sledge GW , Shapiro CL, Ingle JN, Lew D, Hutchins LF,
Livingston RB, Martino S. Sequenced vs. Simultaneous Anthracycline and Cyclophosphamide in High Risk
Stage I-II Breast Cancer: Final Analysis From INT-0137 (S9313). Journal of Clinical Oncology 2007, 25(6):
656-661.
82. Gotay CC, Moinpour CM, Unger JM, Jiang C, Ankerst DP, Coleman D, Martino S, Parker B, Bearden J,
Dakhil S, Gross H, Lippman S, Albain KS.Impact of a Peer-Delivered Telephone Intervention for W omen
Experiencing a Breast Cancer Recurrence. J Clin Oncol. 2007, 25(15):2093-9.
83. Hayes DF, Thor A, Dressler L, W eaver D, Edgerton S, Broadwater G, Goldstein L, Martino S, Ingle J,
Henderson IC, Berry D. HER2 and response to paclitaxel in node-positive breast cancer.. N Engl J Med.
2007, 357(15):1496-506.
84. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE,
Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater
JL; National Cancer Institute of Canada Clinical Trials Group MA.17. Efficacy of letrozole extended adjuvant
therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National
Cancer Institute of Canada Clinical Trials Group MA.17. J Clin Oncol. 2007, 25(15):2006-11.
85. Ingle JN, Tu D, Pater JL, Muss HB, Martino S, Robert NJ, Piccart MJ, Castiglione M, Shepherd LE,
Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Goss
PE. Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early
breast cancer: NCIC CTG MA.17. Ann Oncol. 2008,19(5):877-82.
Silvana Martino, D.O.
Curriculum Vitae
Page 14
Original Observations in Journals (continued):
86. Sparano JA, W ang M, Martino S, Jones V, Perez EA, Saphner T, W olff AC, Sledge GW Jr, W ood W C,
Davidson NE. W eekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med. 2008,
358(16):1663-71.
87. Perez EA, Suman VJ, Davidson NE, Sledge GW , Kaufman PA, Hudis CA, Martino S, Gralow JR, Dakhil
SR, Ingle JN, W iner EP, Gelmon KA, Gersh BJ, Jaffe AS, Rodeheffer RJ. Cardiac safety analysis of
doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central
Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol. 2008, 26(8):1231-8.
88. Ganz PA, Hussey MA, Moinpour CM, Unger JM, Hutchins LF, Dakhil SR, Giguere JK, Goodwin JW ,
Martino S, Albain KS. Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on
Southwest Oncology Group protocol s8897. J Clin Oncol. 2008, 26(8):1223-30.
89. Muss HB, Tu D, Ingle JN, Martino S, Robert NJ, Pater JL, W helan TJ, Palmer MJ, Piccart MJ, Shepherd
LE, Pritchard KI, He Z, Goss PE. Efficacy, toxicity, and quality of life in older women with early-stage breast
cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17. J Clin
Oncol. 2008, 26(12):1956-64.
90. Goss PE, Ingle, JN, Pater JL, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione, Tu D, Shepherd LE,
Pritchard KL, Lingingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ,
Dongsheng T. Late Extended adjuvant treatment with Letrozole improves outcome in women with earlystage breast cancer after completing five years for Tomaxifen. Journal of Clinical Oncology 26(12): 19481955, 2008.
91. Goodwin JW , Green SJ, Moinpour CM, Bearden JD, Giguere JK, Jiang CS, Lippman SM, Martino S, Albain
KS. A phase III randomized placebo-controlled trial of two doses of megestrol acetate as treatment for
sympotom of ovarian failure in women treated for breast cancer: Southwest Oncology Group Study 9626. J
Clin Onc. 2008, 26(10): 1650-1656.
92. Badve SS, Baehner FL, Gray RP, Childs BH, Maddala T, Liu ML, Rowley SC, Shak S, Perez ED, Shulman
LJ, Martino S, Davidson NE, Sledge GW , Goldstein LJ, Sparano JA. Estrogen- and progesterone-receptor
status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and
quantitative reverse transcription polymerase chain reaction by central laboratory. J Clin Oncol. 2008,
26(20):3472.
93. Goldstein LJ, Gray R, Badve S, Childs BH, Yoshizawa C, Rowley S, Shak S, Baehner FL, Ravdin PM,
Davidson NE, Sledge GW Jr, Perez EA, Shulman LN, Martino S, Sparano JA. Prognostic utility of the 21gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic
features. J Clin Oncol. 2008, 26(25):4063-4071
94. Goldstein L, O'Neill A, Sparano J, Perez E, Shulman L, Martino S, and Davidson N. Concurrent doxorubicin
plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast
cancer with 0-3 positive axillary nodes: results of North American Breast Cancer Intergroup Trial E 2197. J
Clin Oncol. 2008, 26(25):4092-4099.
95. Halyard MY, Pisansky TM, Dueck A, Pierce LG, Solin LJ, Marks LB, Davidson NE, Martino S, Kaufman PA,
Kutteh LA, Dakhil SR, Perez EA. Radiotherapy and Adjuvant Trastuzumab in Stage I-IIA Breast Cancer:
Tolerability and Adverse Event Data From the North Central Cancer Treatment Group Phase 3 Trial N9831
J Clin Oncol. 2009, 27(16):2638-2644
96. Hershman DL, Unger JM, Barlow W , Hutchins L, Martino S, Osborne K, Livingston R, and Albain KS.
Treatment Quality and Outcomes of African American versus Caucasian Breast Cancer Patients:
Retrospective Analysis of Southwest Oncology Group Studies S8814/S8897. J Clin Oncol. 2009,
27(13):2157-2162.
Silvana Martino, D.O.
Curriculum Vitae
Page 15
Original Observations in Journals (continued):
97. Choi JY, Barlow W E, Albain K, Hong C-C, Blanco JG, Livingston R, Davis W , Rae JM, Yeh IT, Hutchins LF,
Ravdin P8, Martino S, Lyss AP, Osborne K, Abeloff M, Hayes DF, Ambrosone CB. Nitric oxide synthase
(NOS3) variants and disease-free survival among treated and untreated breast cancer patients in a SW OG
Clinical Trial (S8897). Clin Cancer Res. 2009, 15(16):5258-5266.
98. Ambrosone CB,, Barlow W E, Reynolds W , Livingston RB, Yeh I-T, Choi J-Y, Davis W , Rae JM, Tang L,
Hutchins L, Ravdin P, Martino S, Osborne CK, Lyss AP, Hayes DF, and Albain KS. Myeloperoxidase
Genotypes and Enhanced Efficacy of Chemotherapy for Early Stage Breast Cancer in SWOG 8897. J Clin
Oncol. 2009, 27(30):4973-4979.
99. Sparano JA, Goldstein LJ, Childs BH, Shak S, Brassard D, Badve S, Baehner R, Bugarini R, Rowley S,
Perez EA, Shulman L, Martino S, Davidson NE, Sledge GW , and Gray R. Relationship between
Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer. Clin
Cancer Res. 2009, 15(24):7693-7700.
100. Slovak ML, Bedell V, Lew D, Albain KS, Ellis GK, Livingtston RB, Martino S, Perez E, Hortobagyi, Sher D,
Stock W . Screening for clonal hematopoiesis as a predictive marker for development of therapy-related
myeloid neoplasia (t-MN) following neoadjuvant therapy in breast cancer (S0012): A South W est Oncology
Group Study. Breast Cancer Res Treat. 2010, 119(2):391-398.
101. Albain KS, Barlow W E, Ravdin PM, Farrar W B, Burton GV, Ketchel SJ, Cobau CD, Levine EG, Ingle JN,
Pritchard KI, Lichter AS, Schneider DJ, Abeloff MD, Henderson IC, Muss HB, Green SJ, Lew D, Livingston
RB, Martino S, Osborne CK; Breast Cancer Intergroup of North America. Adjuvant chemotherapy and
timing of tamoxifen in postmenopausal with endocrine-responsive, node-positive breast cancer: A phase 3,
open-lable, randomised controlled trial. Lancet. 2010 (374): 2055-2063.
102. Edith A. Perez, Robert B. Jenkins, Amylou C. Dueck, Anne E. W iktor, B.S.2, Patrick P. Bedroske, Anderson
SK, Ketterlillng RP, Sukov W R, Manehira K, Beiyun Chen, Geiger XJ, Andorfer CA, McCullough AE,
Davidson NE, Martino S, Sledge GW , Kaufman PA, Kutteh LA, Gralow JR, Harris LN, Ingle JN, Lingle W L,
Reinholz MM. C-MYC Alterations and Association with Patient Outcome in Early-Stage HER2+ Breast
Cancer from the NCCTG Adjuvant Trastuzumab Intergroup Trial N9831. J Clin Oncol. 2011 feb
20;29(6):651-9.
103. Sparano JA, Goldstein LJ, Childs BH, Shak S, Brassard D, Badve S, Baehner FL, Bugarini R, Rowley S,
Perez E, Shulman LN, Martino S, Davidson NE, Sledge GW Jr, Gray R. Relationship between
Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer. Clin
Cancer Res. 2009, 15(24):7693-7700.
104. Perez E, Reinholz M, Hillman D, Tenner K, Schroeder M, Davidson N, Martino S, Sledge G, Harris N,
Gralow J, Dueck A, Ketterling R, Ingle J, Lingle W , Kaufman P, Visscher D. Jenkins R. HER2 and
Chromosome 17 Effect on Patient Outcome in the N9831 Adjuvant Trastuzumab Trial. Journal of Clinical
Oncology. 2010,28(28):4307-4315
105. Perez, EA, Romond EH, Susman VJ, Jeong J-H, Davidson NE, Geyer CE, Martino S, Mamounas EP,
Kaufman PA, W olmark N. Four–year follow-up of transtuzumab plus adjuvant chemotherapy for operable
human epidermal growth factor receptor 2-positive breast cancer:joint analysis of data from NCCTG N9831
and NSABP B-31. Journal of Clinical Oncology. 2011,29(25):3366-3373
106. Lara J, Thor A, Dressler L, Broadwater G, Bleiweiss I, Edgerton S, Cowan D, Goldstein L, Martino S, Ingle
J, Henderson I, Norton L, W iner E, Hudis C, Ellis M, Berry D, Hayes D. p53 Expression in Node Positive
Breast Cancer Patients: Results from the Cancer and Leukemia Group B(CALGB) 9344 Trial. Clinical
Cancer Research. 2011, 17(15):5170-5178
Silvana Martino, D.O.
Curriculum Vitae
Page 16
Original Observations in Journals (continued):
107. Sparano JA, Goldstein LJ, Childs BH, Shak S, Brassard D, Badve S, Baehner FL, Bugarini RL, Rowley S,
Perez EA, Shulman LN, Martino S, Davidson NE, Kenny PA, Sledge GW , Jr., and Gray R. Relationship
Between quantitative GRB7 RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in
Triple Negative Breast Cancer. Clin Cancer Res. 2011 Nov 15;17(22): 7194-203
108. Sparano J, W ang M, Zhao F, Stearns V, Martino S, Ligibel JA, Perez EA, Saphner T, W olff A, Sledge G,
W ood W C, Davidson NE. Race and Hormone Receptor-Positive Breast Cancer Outcomes in a Randomized
Chemotherapy Trial. J Natl Cancer Inst. 2012 Jan 16.(Epub ahead of print)
109. Sparano J, W ang M, Stearns V, Martino S, Perez E, Saphner T, W olff A, Sledge G, W ood W , Fetting J,
Davidson N. Obesity at diagnosis is associated with inferior outcomes in hormone receptor operable breast
cancer. ( accepted by JCO January 2012)
110. Bagaria SP, Ray PS, W ang J, Kropcho L, Chung A, Sim MS, Shamonki JM, Martino S, Cui X, Giuliano AE.
Prognostic value of basal phenotype in HER2-overexpressing breast cancer. Ann Surg Oncol. 2012
Mar;19(3):935-40
111. Schneider B, Zhao F, W ang M, Stearns V, Martino S, Jones V, Perez E, Saphner T, W olff A, Sledge G,
W ood W , Davidson N, Sparano J. Neuropathy is not associated with clinical outcomes in patients receiving
adjuvant taxane-containing therapy for operable breast cancer. ( accepted for publication by Journal of
Clinical Oncology, January 2012).
112. Solin L, Gray R, Goldstein L, Recht A, Baehner F, Shak S, Badve S, Perez E, Shulman L, Martino S,
Davidson N, Sledge G, Sparano J. Prognostic value of biologic subtype and the 21-gene recurrence score
relative to local recurrence after breast conservation treatment with radiation for early stage breast
cancinoma: results from the Eastern Cooperative Oncology Group E2197 Study. ( accepted by Breast
Cancer Research and Treatment, April 2012).
113. Sukov W Reinholz M, Hillman D, Dueck A, Miller D, Tenner K, Ketterling R, Kaufman P, Davidson N,
Dakhil S, Martino S, Andorfer C, Jenkins R, Perez E. Benefit of Adjuvant Trastuzumab in Breast Cancer
Patients with Focal HER2 Amplified Clones: Data from the N9831 Trastuzumab Adjuvant Trial. ( accepted
by Clinical Cancer Research, 3-2012)
114. Perez E, Martino S. C-MYC Protein Expression and Gene Amplification and Association with Patient
Outcome in Early-Stage HER+ Brest Cancer from the North Central Cancer Treatment Group Adjuvant
Trastuzumab Trial N9831. (accepted for publication 8-12 JCO)
115. Perez E, Dueck A, McCullough A, Chen B, Geiger X, Jenkins R, Lingle W , Davidson N, Martino S, Kaufman
P, Kutteh L, Sledge G, Harris L, Gralow J, Andorfer C, Reinholz M. Impact of PTEN protein expression on
benefit to adjuvant trastuzumab in early-stage HER2+ breast cancer in NCCTG adjuvant trial N9831,
(submitted to J Clin Onc, 1-2012)
116. Patel T, Moreno-Aspitia A, Kutteh L, Jaffe A, Hobday T, LaPlant B, Hillman D, Gersh B, Rodeheffer R,
Kaufman P, Davidson N, Martino S, Perez E. Role of Circulating Cardiac Markers from the Adjuvant
N9831Clinical Trial. (accepted by American Association for Cancer Research, December,2011)
117. Sparano J, Goldstein L, Childs B, Yoshizawa C, W atson D, Rowley S, Shak S, Badve S, Baehner F,
Davidson N, Sledge G, Perez E, Shulman L, Martino S, Gray R. Association of individuals genes associated
with recurrence in operable breast cancer treated with adjuvant chemotherapy. (In preparation
118. Shulman L, Cirrincione C, Berry D, Becker H, Perez E, O’Regan R, Martino S, Atkins J, Mayer E, Schneider
C, Kimmick G, Norton L, Muss H, W iner E, Hudis C, Six cycles of doxorubicin and cyclophophamide or
paclitaxel are not superior to 4 cycles as adjuvant chemotherapy for breast cancer in women with 0-3
positive axillary nodes. (published ahead of print on July 23, 2012, JCO)
Silvana Martino, D.O.
Curriculum Vitae
Page 17
119. Goss P, Ingle J, Martino S, Tobert N, Muss H, Livingston R, Davidson N, Perez E, Cameron D, Pritchard K,
W helan T, Shepherd L, Tu D. Analysis of women premenopausal at diagnosis entered on the placebocontrolled NCIC CTG MA17 trial of extended adjuvant Letrozole. (submitted to Lancet Oncology, March
2012))
Review Articles:
1.
Martino, S. Interferon. Osteopathic Medicine, 1980;5(11):55-80.
2.
Singhakowinta, A., Samal, B.A., Martino, S., Vaitkevicius, V.K. Is Hormone Sensitivity in Breast Cancer
Related to Responsiveness to Cytotoxic Therapy? Reviews on Endocrine-Related Cancer, 1982;11:15-19.
3.
Olevsky O, Martino S. Randomized clinical trials of raloxifene: Reducing the risk of osteoporosis and breast
cancer in postmenopausal women. Menopause. 2008;15(4 Suppl):790-796.
4.
Chung C, Martino S. Inflammatory Breast Cancer: the Road to Progress. Oncology. 2011;25(3):280-282
Books and Chapters:
1.
Martino S, Baker LH, Pollard RJ, Correa JJ, DeMattia MD. Pulmonary Toxicity of Mitomycin. In: Mitomycin-C
Current Status and New Developments. Carter and Crooke, editors. Academic Press; 1979.p. 231-42.
2.
Djuric Z, Martino S, Heibrun LK, Hart RW . Dietary modulation of oxidation DNA damage. In: Diet & Cancer:
Markers, Prevention and Treatment. Marge B. Jacobs, editor. Plenum Press, New York, NY, 1994. p 71-73.
5.
Martino, S., The Role of Medical Oncology in an Interdisciplinary Comprehensive Breast Center. Surgical
Oncology Clinics of North America, Volume 9, Number 2, April 2000.
Case Reports:
1.
Martino S. Danazol induced hypercalcemia in breast cancer. Breast Cancer Research and Treatment,
1984;4(1):53.
2.
Martino S, Singhakowinta A. Serial interferon alpha2 levels in serum and cerebrospinal fluid. Cancer
Treatment Reports 1984;68:1057-58.
3.
Martino S, Samal, BA, Sohn YH. Reversible cardiac arrhythmia in a breast cancer patient treated with
recombinant alpha interferon. Breast Cancer Research and Treatment 1985; 5:327-29.
4.
Martino S, Young JD, Schilcher, RB. Treatment of a hyperbilirubinemic patient with doxorubicin: clinical and
pharmacokinetic results. Hellan and S.A. Eccles, editors. In: Treatment of Metastases: Problems and
Prospects Proceedings, 1985. p. 61-64, K.
PUBLISHED ABSTRACTS:
1.
Martino S, Ownby H, Russo J, Roi L, Brennan MJ. Interrupted Pregnancy as an Indicator of Prognosis in
Primary Breast Bancer. 5th Annual San Antonio Breast Cancer Symposium, Breast Cancer Research and
Treatment. 2;15-19:#20, 1982 Nov 5-6.
Silvana Martino, D.O.
Curriculum Vitae
Page 18
2.
Martino S, Samal BA, Singhakowinta A, Decker DA, Haas CD. In Vivo and In Vitro Study of AZQ in
Advanced Breast Cancer. Proceedings of the American Society of Clinical Oncology, C-496:127, March
1984
3.
Decker DA, Martino S, Subramanian MG. Inhibition of Androgen Steroidogenesis by Ketoconazole and
Dexamethasone in Patients with Metastatic Prostate Cancer. Proceedings of the American Society of
Clinical Oncology, C-633:162, March 1984.
4.
Martino S, Schilcher RB, Ownby H, Russo J, Roi J, Brennan MJ. Interrupted Pregnancies (IP) as a Risk
Factor in Primary Breast Cancer. J. Cancer Res Clin Oncol 1984;107(Suppl S-21).
5.
Rooney,M, Singhakowinta A, Samal,BA, Martino S, Powers W . Multifocal Spinal Metastases from Breast
Cancer: A Role for W hole Spine Irradiation? Proceedings of the American Society of Clinical Oncology,
C-500:128, March 1984.
6.
Schilcher RB, Decker DA, Evans L, Martino S, Kresge C, Young JD, Samal BA, Singhakowinta A. Influence
of Age on Pharmacokinetics of 5-Fluorouracil (5FU). Breast Cancer Research and Treatment, 4(4)347,#52,
1984.
7.
Martino S, Ratanatharathorn V, Karanes C, Samal BA, Sohn YS, Rudnick SE. Reversible Arrhythmias
Observed in Patients Treated with Recombinant DNA-Alpha2 Interferon. Breast Cancer Research and
Treatment, 4(4):338,#15, 1984.
8.
Martino S, Schilcher RB, Marier SJ, Evans LJ, Allen BJ, Young JD. Clinical and Pharmacokinetic Results in
a Breast Cancer Patient with Hyperbilirubinemia Treated with Doxorubicin (DOX). Breast Cancer Research
and Treatment, 4(4):347, #50, 1984.
9.
Martino S, Schilcher RB, Baker LH. Abgebrochene Schwangershaft (IP)-Ein prognostisches Zeichen bei
Patientinnen mit Primaerem Mammakarzinom, (17). Deutscher Krebskongress, Muenchen, FRG, March
7-10, Verh. Dtsch. Krebsgesellshaft 5, 1984.
10. Martino S, Samal BA, Vaitkevicius VK. Phase II Study of Deoxydoxorubicin as First Line Therapy in
Advanced Breast Cancer. Proceeding of the American Society of Clinical Oncology, C-259,4(4):67, March
1985.
11. Ratanatharathorn V, Karanes C, Al-Sarraf M, Kish J, Ensley J, Pazdur R, Martino S, Young J, Rish P,
Konrad M, Galicky P. Phase I trial of serine substituted recombinant DNA Beta Interferon (b-IFN).
Proceedings of AACR, 26:274,#1079, March 1985.
12. Martino S, Samal B, Vaitkevicius VK, Brennan MJ, Kresge C. 4`Deoxydoxorubicin (DxDx) as First Line
Therapy for Metastatic Breast Cancer. Breast Cancer Research and Treatment, 6(2):171,#30, 1985.
13. Appel J, Singhakowinta A, Martino S, Bergsman KL, Samal BA. Repeat Combination Chemotherapy
Following Adjuvant Use in Advanced Breast Cancer. Proceedings of the American Society of Clinical
Oncology, 5:60,#234, May, 1986.
14. Fabian C, Park C, Jewell W , Kimler B, Lin F, Martino S, Osborne CK. Increase in proliferation fraction in
breast cancer in vivo following estradiol vaginal suppositories as demonstrated by serial biopsies and flow
cytometry. Proceedings of AACR, #29, March 1988.
15. Valdivieso M, Pazdur R, Flaherty L, Martino S, Redman B, W ozniak A, Herskovic A, Baker L. Intensive
chemotherapy (INT-RX) of small cell lung cancer (SCLC) with weekly etoposide (E), cyclophosphamide (C),
hydroxydaunorubicin (H) and oncovin (O)-echo. Proceedings of the American Society of Clinical Oncology,
Vol. 7, March 1988.
16. Flaherty L, Redman B, Chabot G, Martino S, Valdivieso M. Combination of dacarbazine (DTIC) and
interleukin-2 (IL-2) in metastatic malignant melanoma (MMM). Proceedings of the American Society of
Clinical Oncology, Vol. 7, March 1988
Silvana Martino, D.O.
Curriculum Vitae
Page 19
17. Ensley J, An ., Martino S, W eaver D, Benitez P, Valeriote F, Heilbrun L. Flow cytometry and cytology from
fine needle aspirates of breasts from women at high risk for breast cancer. Breast Cancer Research and
Treatment 12:87-105, 1988.
18. Martino S, Gala R, Valeriote F, Kim P, Heilbrun L, Kresge C, Boomer A. Prolactin as a predictor of breast
cancer risk. Breast Cancer Research and Treatment, 12:87-105, 1988.
16. Flaherty L, Redman B, Martino S, Valdivieso M, Rudolph A. Sequential recombinant interleukin-2 (rIL-2)
and dacarbazine (DTIC) (RID-1) in metastatic malignant melanoma (MMM) clinical and immunologic results.
Society for Biological Therapy, November 6-10, 1988.
20. Redman, B., Flaherty, L., Chou, T.H., Martino, S., Al-Katib, A., Kaplan, J., Valdivieso, M. Phase I trial of
combination therapy with recombinant interleukin-2 (IL-2) and recombinant interferon-gamma (IFN-g) in
patients with cancer. Proceedings of the American Society of Clinical Oncology, 8:189, 1989.
21. Martino S, Ensley JF, W eaver D, Benitez P, An T, Maciorowski Z, deBraud F, Hassan M, Kukuruga M,
Singhakowinta A, Valeriote F. Cellular DNA content characteristics of needle aspirates from patients at high
risk for developing breast cancer. Proceedings AACR, 30:#1018, 1989.
22. Boomer A, Martino S, Krag G, Liang D, Bacus J, Reading B, Heilbrun L. Compliance to a 15% fat diet in
women at risk for breast cancer. Breast Cancer Research and Treatment, 14:1, 1989.
23. Flaherty L, W ozniak A, Redman B, Martino S, Valdivieso M. Phase II-5FU, VP-16, Cisplatin (FED) in
Metastatic Non-Small Cell Lung Cancer (NSCLC). Proceedings of the American Society of Clinical
Oncology, 30:614, 1989.
24. Gordon CJ, Valdivieso M, Martino S, Redman BG, Flaherty L, Baker LH. Continuous intravenous
5-flourouracil (5-FU) infusion, weekly adriamycin (ADR) and oral cyclophosphamide (CTX) [FAC-CI] in the
treatment of metastatic carcinoma (MCB). Proceedings of the American Society of Clinical Oncology,
1(9):52, #200, 1990.
25. Valdivieso M, W ozniak A, Flaherty L, Pazdur R, Herskovic A, Heilbrun L, Redman B, Martino S, Baker L.
Efficacy of weekly chemotherapy for small cell lung cancer (SCLC). Proceedings of the American Society of
Clinical Oncology, 1(9):238, #920, 1990.
26. Martino S, Piccart MJ, Dodion PF, Chuang-Stein C, Flaherty L, Redman B, Valdivieso M, English PA,
Earhart RH. Phase II study of daily x 3 oral menogaril in advanced breast cancer. Proceedings of the
American Society of Clinical Oncology, 1(9):52, #198, 1990.
27. Flaherty L, Robinson W , Redman B, Gonzales R, Martino S, Kraut M, Valdivieso M, Rudolph A. A phase II
study of dacarbazine (DTIC), cisplatin (DDP), and outpatient interleukin-2 (IL-2) (RIDD-2) in metastatic
malignant melanoma (M.M.M.). Proceedings of the American Society of Clinical Oncology, 1(9):187, #723,
1990.
28. Redman. B.G., Flaherty, L., Chou, T.H., Al-Katib, A., Kraut, M., Martino, S., Chen, B., Kaplan, J. and
Valdivieso, M. A phase I trial of recombinant Interleukin-2 combined with recombinant Interferon-Gamma in
patients with cancer. J. Clin. Oncol. 8:1269-1276, 1990.
29. Negendank W , Crowley MG, Al-Katib A, Al-Sarraf M, Martino S, Samal B, Zalupski MM, Baker LH.
Assessment of 31P MRS chemotherapy response predictor in man using quantative spectral reproducibility
criteria. Society of Magnetic Resonance in Medicine. New York, August, 1990.
30. Flaherty L, Redman B, Martino S, Kraut M, Simon M, Valdivieso M, Louie A. High-dose Decarbazine (DTIC)
and CIsplatin (DDP) Alone and Combined W ith Outpatient Interleukin-2 (IL-2) in Metastatic Malignant
Melanoma (MMM). Proceedings of the American Society of Clinical Oncology, 9:187, 1990.
31. Djuric Z, Heilbrun LK, Valeriote FA, Martino S. Effects of a low-fat diet on oxidative DNA damage in white
blood cells of women at high risk for breast cancer. Oxidative Damage and Repair - Fifth Bi-Annual Meeting
of the International Society for Free Radical Research. Free Radical Biol. Med., 9 (Suppl. 1):55, 1990.
Silvana Martino, D.O.
Curriculum Vitae
Page 20
32. Chlebowski RT, Rose D, Blackburn G, Buzzard M, Khandekar J, York R, Insull W , Martino S, Elashoff R,
W ynder E. Feasibility of using dietary fat intake reduction in adjuvant breast cancer management.
Proceedings of the American Society of Clinical Oncology, 10:86, #217: 1991.
33. Lemanne D, Simon M, Martino S, Swanson M. Breast carcinoma in situ (CIS): Greater rise in ductal
carcinoma in situ (DCIS) vs. lobular carcinoma in situ (LCIS). Proceedings of the American Society of
Clinical Oncology, 10,(55):45, 1991.
34. Redman B, Flaherty L, Chou TH, Kraut M, Martino S., Simon ML, Groves E. Phase I trial of recombinant
macrophage-colony stimulating factor (M-CSF) by rapid intravenous (IV) infusion in patients with cancer.
Proceedings of the American Society of Clinical Oncology, 10:98,262 1991.
35. Simon, M., Schwartz, A., Martino, S., Swanson, M. Trends in the diagnosis of in situ breast cancer in the
Detroit Metropolitan Area. Proceedings of the American Society of Clinical Oncology 10:132, #395, 1991.
36. Kraut M, W ozniak A, Flaherty L, Redman B, Samal B, Martino S, Simon M, Valdivieso M. Treatment of
metastatic non-small cell lung cancer (NSCLC) with mitomycin, etoposide, and cisplatin (MEP). Proceedings
of the American Society of Clinical Oncology 10:262, #907, 1991.
7.
Simon M, Lemanne D, Martino S, Schwartz A, Swanson GM. Trends in the Incidence of In Situ and
Invasive Breast Cancer in the Detroit Metropolitan Area. Breast Cancer Research and Treatment, 19(2):165,
1991.
38. Simon MS, Martino S, Hussein M, Hoff M, W alt A, Meyer L. A survey of medical follow-up practice in
women with early stage invasive breast cancer. Proceedings of the American Society of Clinical Oncology,
11:87,#175, 1992.
39. Flaherty L, Redman B, Martino S, Kraut M, Simon M, Samal B, Valdivieso M, Louie, A. High-dose
decarbazine (DTIC) and cisplatin (DDP) alone and combined with outpatient interleukin (IL-2) in metastatic
malignant melanoma (MMM). Proceedings of the American Society of Clinical Oncology, 11:350,#1206
1992.
40. Ensley JF, W eaver D, Benitez P, An T, Maciorowski Z, del Alonso M, Kukuruga M, Martino S. Dietary
modulation of abnormal DNA histograms from breast aspirates of patients at high risk for developing breast
cancer. Proceedings AACR, 33:133, 1992.
41. Simon M, Hoff M, Hussein M, Martino S. A study of clinical follow-up in women with early stage breast
cancer. 15th Annual San Antonio Breast Cancer Symposium, 1992.
42. Chlebowski RT, Blackburn GL, Buzzard IM, Rose DP, Martino S, Khandekar JD, York MR, Jeffery RW ,
Elashoff RM, W ynder EL. Adherence to Dietary Fat Intake Reduction in Postmenopausal W omen with
Resected Breast Cancer. Proceedings of the American Society of Clinical Oncology, 12:269, #473, 1993.
43. Lichter A, Green S, Albain K, Hutchins L, Martino S. The Influence of Patient Characteristics,
Socioeconomic (SES) Factors, Geography, and Systemic Risk on the Use of Breast Sparing Treatment in
the Adjuvant Breast Cancer Studies. Proceedings of the American Society of Clinical Oncology, 13:62, #51,
1994.
44. Djuric Z, Simon MS, Luongo DA, LoRusso PM, Martino S. Oxidative DNA Damage in Blood DNA as a
Marker of Breast Cancer Risk. Proceedings AACR 35:286. 1994.
45. Djuric Z, Simon MS, Luongo DA, LoRossu PM, Martino S. Oxidative DNA damage in blood DNA as a
marker of breast cancer risk. American Cancer Society, Michigan Division Meeting; Detroit, MI,
Nov. 18, 1994.
46. Appelbaum FR, Armitage JO, Bierman PJ, Bitran JD, Buzdar A, Dubois R, Fisher RI, Gale RP, Hortobagyi
GN, Jones SE, Lazar GS, Loh KK, Martino S, Peterson BA, Phillips GL, Portlock CS, Rosenblum D, Shipp
MA, Shpall EJ, Spitzer G, Swain SM, Vaughn CB, Vogel C. Comparison of Rand-Delphi Analysis of
Silvana Martino, D.O.
Curriculum Vitae
Page 21
Appropriateness of Bone Marrow and Blood Cell Autotransplants in Breast Cancer and Non-Hodgkin
Lymphomas. Proceedings of the American Society of Clinical Oncology, 14:314, #922, 1995.
47. Katato K,.Simon M, Martino S, Flaherty L, Redman B,. Lorusso P, Kellogg C, Hughes R. A Phase II Trial of
Oral Altretamine (Hexalen) for the Treatment of Metastatic Breast Cancer. Proceedings of the American
Society of Clinical Oncology, 14:119, #174, 1995
48. Taylor CW , Green S, Dalton W S, Martino S, Ingle JN, Robert NJ, Rector DJ, Osborne CK. A Multi-Center
Randomized Trial of Zoladex Versus Surgical Ovariectomy in Pre-Menopausal Patients with Receptor
Positive Metastatic Breast Cancer. Breast Cancer Research and Treatment 37:37, 1995.
49. CE Geyer Jr, SJ Green, C Moinpour, J O'Sullivan, D Goodwin, V Canfield, V Hamaski, S Martino. A Phase
II Trial of Paclitaxel in Patients with Metastatic Refractory Carcinoma of the Breast: A Southwest Oncology
Group (SW OG) Study. Proceedings of the American Society of Clinical Oncology 15:107, #92, 1996.
50. Rivkin SE, Green S, O'Sullivan J, Glucksberg H, Gadel-Mawla N, Constanzi JJ, Hoogstraten B, Athens J,
Maloney T, Osborne CK, Vaughn CB, and Martino S. Adjuvant CMFVP Versus Melphalan for Operable
Breast Cancer with Positive Axillary Nodes: 20-Year Results of a Southwest Oncology Group Study. Breast
Cancer Research and Treatment, 41(3):219, #2, 1996.
51. Albain K, Green S, Osborne K, Cobau C, Levine E, Ingle J, Pritchard K, Schneider D, O'Sullivan J, Hess E,
Martino S. Tamoxifen (T) vs. Cyclophosphamide, Adriamycin, and 5-FU (CAF) plus Either Concurrent or
Sequential T in Postmenopausal, Receptor (+), Node (+) Breast Cancer: A Southwest Oncology Group
Phase III Intergroup Trial. Proceedings of the American Society of Clinical Oncology, 16:128a,#450, 1997.
52. Sledge Jr GW , Neuberg D, Ingle J, Martino S, W ood W . Phase III Trial of Doxorubicin(A) vs. Paclitaxel(T)
vs. Doxorubicin+Paclitaxel(A+T) as First-Line Therapy for Metastatic Breast Cancer(MBC): An Intergroup
Trial. Proceedings of American Society of Clinical Oncology,16:1a, #2, 1997.
53. Elledge R, Green S, Allred D, Clark G, Ravdin P, Martino S, Osborne CK. ER and PGR by Ligand Binding
Assay Compared with ER, PGR and PS2 by IHC in Predicting Response to Tamoxifen in Metastatic Breast
Cancer. Breast Cancer Research and Treatment, 46(1):65, #258, 1997.
54. Hutchins L, Green S, Ravdin P, Lew D, Martino S, Abeloff M, Lyss A, Henderson IC, Allred C, Dakhil S,
Pierce I, Goodwin W , Thompson I, Rivkin S, Chapman R, Osborne CK. CMF versus CAF with and without
Tamoxifen in High-Risk Node-Negative Breast Cancer Patients and a Natural History follow-up Study in LowRisk Node-Negative Patients: First Results of Intergroup Trial Int 0102: A Southwest Oncology Group
Study. Proceedings of the American Society of Clinical Oncology, 17:1a, #2, 1998.
55. P.M. Ravdin, S. Green, K.S. Albain, V. Boucher, J. Ingle, K. Pritchard, L. Shepard, N. Davidson, D.F.
Hayes,G.M. Clark, S. Martino, C.K. Osborne, D.C. Allred. Initial Report of the SW OG Biological Correlative
Study of C-ERBB-2 Expression as a Predictor of Outcome in a Trial Comparing Adjuvant CAF T with
Tamoxifen (T) alone. Proceedings of the American Society of Clinical Oncology 17:97a,#374, 1998.
56. Henderson IC, Berry D, Demetri G, Cirrincione C, Goldstein L, Martino S, Ingel JN, Cooper MR, Canellos G,
Borden E, Fleming G, Holland JF, Graziano S, Carpenter J, Muss H, Norton L. Improved disease-free (DFS)
and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of
doxorubicin (A) dose level in the adjuvant chemotherapy of patients (PTS) with node-positive primary breast
cancer (BC). Proceedings of the American Society of Clinical Oncology, 17:101a, 390A, 1998.
57. Silverstein MJ, Lagios MD, W aisman JR, Martino S, Baron P, Lewinsky BS, Colburn W J,. Gamagami P.
Margin W idth: A Critical Determinant of Local Control in Patients with Ductal Carcinoma in Situ (DCIS) of the
Breast. Proceedings of the American Society of Clinical Oncology, 17:120a, #460, 1998.
58. Davidson N, O’Neil A, Habermann T, Osborne CK, Martino S, W hite D, Abeloff MD for ECOG. Effect of
Chemohormonal Therapy in Premenopausal, Node (+), Receptor (+) Breast Cancer: An Eastern Cooperative
Oncology Group Phase III Intergroup Trial (E5188, INT-0101). Proceedings of the American Society of
Clinical Oncology 18:67a, #249, 1999.
Silvana Martino, D.O.
Curriculum Vitae
Page 22
59. Rivkin SE, Green S, Lew D, Glucksberg H, Gad-el-Mawla N, Costanzi J J, Hoogstraten B, Athens J, Maloney
T, Osborne CK, Vaughn CB, Martino S. Adjuvant CMFVP Versus Melphalan for Operable Breast Cancer
with Positive Axillary Nodes: 23-Year Results of a Southwest Oncology Group Study. Proceedings of the
American Society of Clinical Oncology 18:69a, #259, 1999.
60. Hughes LL, Gray RJ, Solin LJ, Robert NJ, Martino S, Tripathy D, Ingle JN, W ood W C, for ECOG, SW OG,
CALGB, and NCCTG. Efficacy of Irradiation for Ovarian Ablation: Results of a Breast Intergroup Study.
Breast Cancer Research and Treatment, 57(1):107, #440, 1999.
61. Hutchins L, Green S, Ravdin P, Lew D, Martino S. Abeloff M, Lyss A, Henderson C, Allred C, Dakhil S,
Pierce I, Goodwin W , Caton J, Rivkin S, Chapman R, and Osborne K. Southwest Oncology Group
Operations Office, San Antonio, TX. CMF Versus CAF + Tamoxifen in High-Risk Node-Negative Breast
Cancer Patients and a Natural History Follow-up Study in Low-Risk Node-Negative Patients : Update of
Tamoxifen Results. Breast Cancer Research and Treatment, 57(1):25, #1, 1999.
62. Ellis GK, Green SJ, Livingston RB, Budd GT, Rivkin SE, Giguere JK, Gandara DR, W eiss GR, Martino S.
Neoadjuvant Doxorubicin, Cyclophosphamide and G-CSF (AC+G) for Locally Advanced Breast Cancer
(LABC), a Southwest Oncology Group Phase II Study. Proceedings of the American Society of Clinical
Oncology, 19:85a, #326, 2000.
63. Cobleigh A, Gray R, Graham M, Norton L, Martino S, Budd GT, Ingle JN, Davidson NE, W ood W C.
Fenretinide (FEN) vs Placebo in Postmenopausal Breast Cancer Patients Receiving Adjuvant Tamoxifen
(TAM), an Eastern Cooperative Oncology Group Phase III Intergroup Trial (EB193, INT-0151). Proceedings
of the American Society of Clinical Oncology, 19:86a, #328, 2000.
64. Taback B, Giuliano AE, Nguyen DT, Nakayama T, Hansen N, Martino S, Fournier PJ, Hoon D. Tumor
Related Free DNA Microsatellites Detected in Breast Cancer Patients Serum Correlates with Disease
Progression. Proceedings of the American Society of Clinical Oncology, 19:606a, #2385, 2000.
65. Ellerbroek N, Martino S, Mautner B, Botnick L. Adjuvant Paclitaxel and Radiation Therapy for Patients with
Intact Breast Feasibility of Concurrent Treatment. Proceedings of the American Society of Clinical Oncology,
20:11b, #1790, 2001.
66. Albain K, Green S, Ravdin P, Osborne CK, Cobau C, Levine E, Ingle J, Pritchard K, Schneider D, Abeloff M,
Norton L, Lew D, Martino S. Overall Survival After Cyclophosphamide, Adriamycin, 5-FU, and Tamoxifen
(CAFT) is Superior to T Alone in Postmenopausal, Receptor (+), Node (+) Breast Cancer: New Findings
From Phase III Southwest Oncology Group Intergroup Trial SS8814. Proceedings of the American Society of
Clinical Oncology, 20:24a, #94, 2001.
67. Goodwin JW , Green SJ, Giarritta S, Giguere JK, Hoelzer K, Bearden J, Livingston RN, Gralow J, Ganz PA,
Martino S, Albain KS. Double Blind Phase III Trial of Placebo (P) vs. Megestrol Acetate (MA) 20 mg. Vs.
MA 40 mg as Treatment for Symptoms of Ovarian Failure in Breast Cancer Survivors: Initial Results of
Southwest Oncology Group S9626. Breast Cancer Research and Treatment, 24th Annual San Antonio Breast
Cancer Symposium, 69(3): 292, #462, 2001.
68. Martino S, Irwin D, Rowland K. The John W ayne Cancer Institute, Santa Monica, CA; Alta Bates
Comprehensive Cancer Center, Berkeley, CA; Carle Clinic, Urbana, IL. A Phase III Trial of Taxol
(T)/Doxorubicin/Cytoxan (D) (Two Dose Levels) Versus Doxorubicin/Cytoxan (C) Followed by a Comparison
of W eekly Versus Q3 W eekly T in Patients (pts) with Metastatic Breast Cancer (MBC). Proceedings of the
American Society of Clinical Oncology, 21(1):56a, #220, 2002.
69. Haskell CM, Green SJ, Sledge Jr. GW , Shapiro CL, Ingle JN, Lew D, Martino S, Livingston RB, and
Osborne, CK for SW OG, ECOG, CALGB and the NCCTG. Phase III Comparison of Adjuvant High-dose
Doxorubicin plus Cyclophosphamide (AC) Versus Sequential Doxorubicin Followed by Cyclophosphamide
(A>C) in Breast Cancer Patients with 0-3 Positive Nodes (Intergroup 0137). Proceedings of the American
Society of Clinical Oncology, 21(1):36a, #142, 2002.
70. Albain KS, Green SJ, Ravdin PM, Cobau CD, Levine EG, Ingle JN, Pritchard KI, Schneider DJ, Abeloff MD,
Norton L, Henderson IC, Lew D, Livingston RB, Martino S, and Osborne CK for SW OG, ECOG, CALGB,
NCCTG, NCIC-CTG, Loyola University Medical Center, Maywood, IL. Adjuvant Chemohormonal Therapy for
Silvana Martino, D.O.
Curriculum Vitae
Page 23
Primary Breast Cancer Should be Sequential Instead of Concurrent: Initial Results from Intergroup Trial
0100 (SW OG-8814). Proceedings of the American Society of Clinical Oncology, 21(l):37a, #143, 2002
71. Stadtmauer EA, O’Neill A, Goldstein LJ, Crilley PA, Mangan KF, Ingle JN, Brodsky I, Martino S, Lazarus HM,
Erban JK, Sickles C, Glick JH. Conventional-dose Chemotherapy Compared with High-dose Chemotherapy
(HDC) Plus Autologous Stem-cell Transplantation (SCT) for Metastatic Breast Cancer: 5-year Update of the
‘Philadelphia Trial’ (PBT-1). Proceedings of the American Society of Clinical Oncology, 21(1):43a, #169,
2002.
72. Ganz PA, Green SJ, Hutchins L, Martino S, Gralow J, Livingston R, Albain KS (from the Southwest
Oncology Group). Late cardiac effects of adjuvant CMF vs CAF in women with node negative breast cancer
treated on SW OG 8897: initial results from SW OG 9342. Breast Cancer Research and Treatment, 25th
Annual San Antonio Breast Cancer Symposium, 76(1):S157, #639, 2002.
73. Citron M, Berry D, Cirrincione C, Carpenter J, Hudis C, Gradishar W , Ingle J, Martino S, W inder E, Muss H,
Norton L. Superiority of dose-dense (DD) over conventional scheduling (CS) and equivalence of sequential
(SC) vs. combination adjuvant chemotherapy (CC) for node-positive breast cancer (CALGB 9741, INT
C9741). Breast Cancer Research and Treatment, 25th Annual San Antonio Breast Cancer Symposium,
76(1):S32, #15, December 2002.
74. Arpino G, Green S, Allred DC, Ravdin P, Lew D, Martino S, Osborne CK, Elledge R. ErbB-2 amplification,
ErbB-1 expression and tamoxifen response in ER-positive metastatic breast cancer: a SW OG study. Breast
Cancer Research and Treatment, 25th Annual San Antonio Breast Cancer Symposium, 76(1):S67, #232,
December 2002.
75. Davidson NE, O’Neill A, Vukov A, Osborne CK, Martino S, W hite D, Abeloff M. Chemohormonal therapy in
premenopausal node-positive, receptor-positive breast cancer: An Eastern Cooperative Oncology Group
phase III intergroup trial (E5188, INT-0101). Proceedings of the American Society of Clinical Oncology, 22:5,
#15, 2003.
76. Perez EA, Suman VJ, Davidson NE, Kaufman PA, Martino S, Ingle JN, Rodeheffer RJ, Gersh BJ, Jaffe AS.
Effect of doxorubicin plus cyclophosphamide (AC) on left ventricular ejection fraction (LVEF) in the NCCTG
N9831 Intergroup Adjuvant Trial. Proceedings of the American Society of Clinical Oncology, 22:19, #75,
2003.
77. Robert NJ, W ang M, Cella D, Martino S, Tripathy D, Ingle J, Solin LJ, W ood W C. Phase III comparison of
tamoxifen versus tamoxifen with ovarian ablation in premenopausal women with axillary node-negative
receptor-positive breast cancer  3 cm. Proceedings of the American Society of Clinical Oncology, 22:5, #16,
2003.
78. Goldstein LJ, O’Neill A, Sparano JA, Perez EA, Shulman LN, Martino S, W olff AC, Davidson NE. LVEF
assessment of adjuvant doxorubicin/cyclophosphamide (AC) vs. doxorubicin/docetaxel (AT) in early stage
breast cancer: Cardiac safety results of ECOG 2197. Proceedings of the American Society of Clinical
Oncology, 22:19, #73, 2003.
79. Budd G, Green S, Livingston R, O’Bryan R, Martino S, Abeloff M, Rinehart J, Harris J, Tormey D, Osbourne
CK. Long-term follow up of SW OG 8313: CMFVP vs FAC-M as adjuvant therapy of node- positive, ERnegative breast cancer. Breast Cancer Research and Treatment. 26th Annual San Antonio Breast Cancer
Symposium, 82(1):S28, #132, December 2003.
80. Albain KS, Unger JM, Hutchins LF, Rivkin SE, Martino S, Livingston RB, Osborne CK. Outcome of African
Americans on Southwest Oncology Group (SW OG) breast cancer adjuvant therapy trials. Breast Cancer
Research and Treatment. 26th Annual San Antonio Breast Cancer Symposium, 82(1):S12, #21, December
2003.
81. McNabb M, Martino S, Secrest RJ, Bryant K, Powles T, Mershon J. Baseline breast cancer risk
demographics and methodology for the Raloxifene use for the heart (RUTH) and continuing outcomes
relevant to Evista (CORE) Studies. Two breast cancer prevention trials. Int J Gynecol Cancer, 13(S1):2,
2003.
Silvana Martino, D.O.
Curriculum Vitae
Page 24
82. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pater
JL. Updated analysis of the NCIC CTG MA.17 randomized placebo (P) controlled trial of letrozole (L) after
five years of tamoxifen in postmenopausal women with early stage breast cancer. Proceedings of the
American Society of Clinical Oncology, 4:87, #847, 2004.
83. Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon JL, Disch D, Secrest RJ, Cummings SR.
Incidence of invasive breast cancer following 8 years of raloxifene therapy in postmenopausal women with
osteoporosis: Results from the Continuing Outcomes Relevant to Evista (CORE) trial. Proceedings of the
American Society of Clinical Oncology, 4:97, #1000, 2004.
84. Perez E, Martino S. HER2 testing by local, central, and reference laboratories in the NCCTG N9831
Intergroup Adjuvant Trial. Proceedings of the American Society of Clinical Oncology, 4:18, #567, 2004.
85. Unger JM, Crowley JJ, Coltman CA, Hutchins LF, Martino S, Macdonald JS, Gandara DS, Crawford ED,
Livingston RB, Albain KS. Accrual patterns of the Southwest Oncology Group (SW OG) by sex,
race/ethnicity, and age: updated and expanded analyses. Proceedings of the American Society of Clinical
Oncology, 4:520, #6014, 2004.
86. Cauley JA, Martino S, Barrett-Connor E, Powles TJ, Mershon JL, Disch D, Secrest RJ, Cummings SR.
Effect of raloxifene on invasive breast cancer incidence in postmenopausal women stratified by Gail risk
assessment: Results of the Continuing Outcomes of Relevant to Evista® (CORE) trial. Proceedings of the
American Society of Clinical Oncology, 4:101, #1018, 2004.
87. W helan T, Goss P, Ingle J, Pater J, Shepherd L, Palmer M, Tu D, Robert N, Martino S, Muss H.
Assessment of quality of life (QOL) in MA.17, a randomized placebo-controlled trial of letrozole in
postmenopausal women following five years of tamoxifen. Proceedings of the American Society of Clinical
Oncology, 4:6, #517, 2004.
88. Miller DV, Jenkins RB, Lingle W L, Davidson NE, Kaufman PA, Martino S, Dakhil SR, Perez EA. Focal
HER2/neu amplified clones partially account for discordance between immunohistochemistry and
fluorescence in-situ hybridization results: Data from NCCTG N9831 Intergroup Adjuvant Trial. Proceedings
of the American Society of Clinical Oncology, 4:19, #568, 2004.
89. Martino S, Powles T, Cauley J, Mershon J, Disch D, Secrest R, Cummings S. Effect of raloxifene on
incidence of invasive breast cancer in postmenopausal women stratified by baseline serum estradiol:
Results of the Continuing Outcomes Relevant to Evista® trial. Breast Cancer Research and Treatment (26th
San Antonio Breast Cancer Symposium), 88(1):S14, #22, 2004.
90. Berry DA, Cirrincione C, Henderson IC, Citron ML, Budman DR, Goldstein LJ, Martino S, Perez E, Muss HB,
Norton L, Hudis C, W iner EP. Effects of improvements in chemotherapy on disease-free and overall survival
of estrogen-receptor negative, node-positive, early stage breast cancer: 20-year Experience of the Cancer
and Leukemia Group B (CALGB) and U.S. Breast Intergroup. Breast Cancer Research and Treatment (26th
San Antonio Breast Cancer Symposium), 88(1):S17, #29, 2004.
91. Perez EA, Josse RG, Pritchard KI, Ingle JN, Martino S, Findlay BP, Shenkier TN, Tzer RG, Palmer MJ,
Shepherd LE, Tu D, Goss PE. Effect of letrozole versus placebo on bone mineral density in women
completing >5 years (yrs) of adjuvant tamoxifen: ncic ctg ma.17b. Breast Cancer Research and Treatment
(26th San Antonio Breast Cancer Symposium), 88(1):S36, #404, 2004.
92. Gotay CC, Moinpour CM, Jiang CS, Ankerst DP, Coleman D, Martino S, Taylor B, Bearden J, Dakhil S,
Gross H, Albain KS. Enhancing well-being during breast cancer recurrence: preliminary finds from a phase
III study. Breast Cancer Research and Treatment (26th San Antonio Breast Cancer Symposium),
88(1):S140, #3080, 2004.
93. Albain K, Barlow W , O’Malley, F, Siziopikou K, Yeh I-T, Ravdin P, Lew D, Farrar W , Burton G, Ketchel S,
Cobau C, Levine E, Ingle J, Pritchard K, Lichter A, Schneider D, Abeloff M, Henderson IC, Norton L, Hayes
D, Green S, Livingston R, Martino S, Osborne CK, Allred DC. Concurrent (CAFT) versus sequential
(CAF-T) chemohormonal therapy (cyclophosphamide, dosorubicin, 5-fluorouracil, tamoxifen) versus T alone
Silvana Martino, D.O.
Curriculum Vitae
Page 25
for postmenopausal, nod-positive, estrogen (ER) and/or progesterone (PgR) receptor-positive breast cancer:
mature outcomes and new biologic correlates on phase II intergroup trial 0100 (SW OG-8814). Breast
Cancer Research and Treatment (26th San Antonio Breast Cancer Symposium), 88(1); addendum sheet.
94. Martino S, Disch D, Dowsett S, Mershon J. Raloxifene and breast cancer risk reduction based on breast
cancer family history. Obstectrics & Gynecology, 105(4):p4S, 2005.
95. Perez EA, Suman VJ, Davidson NE, Kaufman PA, Martino S, Dakhil SR, Ingle JN, Hillman DW , Rodeheffer
RJ, Gersh BJ, Jaffe AS. Interim cardiac safety analysis of NCCTG N9831 Intergroup adjuvant Trastuzumab
trial. Proceedings of the American Society of Clinical Oncology, 23(16S, I of III):17s, #556, 2005.
96. Goldstein LJ, O’Neill A, Sparano JA, Perez EA, Shulman LN, Martino S, Davidson NE. E2197: Phase III AT
(doxorubucin / docetaxel) vs. AC (doxorubicin / cyclophosphamide) in the adjuvant treatment of node positive
and high risk node negative breast cancer. Proceedings of the American Society of Clinical Oncology,
23(16S, I of III):7s, #512, 2005.
97. Bearman SI, Green S, Gralow J, Barlow W , Hudis C, W olff A, Ingle J, Hortobagyi G, Livingston R, Martino
S. SW OG/Intergroup 9623: A phase III comparison of intensive sequential chemotherapy to high dose
chemotherapy and autologous hematopoietic progenitor cell support (AHPCS) for primary breast cancer in
women with >4 involved axillary lymph nodes. Proceedings of the American Society of Clinical Oncology,
23(16S, I of III):21s, #572, 2005.
98. Martino S, Disch D, Dowsett S, Mershon J. Effect of raloxifene on invasive breast cancer incidence in
postmenopausal women stratified by age (<65 and >65 years). Proceedings of the American Society of
Clinical Oncology, 23(16S, I of III):108s, #1009, 2005.
99. Hudis C, Citron M, Berry D, Cirrincione C, Gradishar W , Davidson N, Martino S, Livingston R, Ingle J, Perez
E, Abrams J, Schilsky R, Ellis M, Muss H, Norton L, W iner E. Five year follow-up of INT C9741: Dose-dense
(DD) chemotherapy (CRx) is safe and effective. Breast Cancer Research and Treatment (28th San Antonio
Breast Cancer Symposium), 94(1):S20, #41, 2005.
100. Perez EA, Suman VJ, Davidson N, Martino S, Kaufman P. Concurrent trastuzumab and paclitaxel treatment
improves disease-free survival in resected HER2-positive breast cancer: NCCTG interim analysis. (Abstract
# 264). ECCO 2005;3(2):74.
101. Perez EA, Suman VJ, Davidson NE, Kaufman PA, Martino S, Dakhil SR, Ingle JN, Rodeheffer RJ, Gersh
BJ, Jaffe AS. Exploratory analysis from NCCTG N9831: Do clinical and laboratory characteristics predict
cardiac toxicity of trastuzumab when administered as a component of adjuvant therapy? Breast Cancer
Research and Treatment (28th San Antonio Breast Cancer Symposium), 94(1):S96, #2038, 2005
102. Mershon J, Disch D, Dowsett S, Martino S. Effect of Raloxifene on invasive breast cancer incidence in
postmenopausal women from USA and Canada. Obstet Gynecol. ( American College of Gynecology 54th
Annual Meeting) 107:81S-82S 2006.
103. Hayes DF, Thor A, Dressler L, W eaver D, Broadwater G, Goldstein L, Martino S, Ingle J, Henderson IC,
Berry D. HER2 predicts benefit from adjuvant paclitaxel after AC in node-positive breast cancer: CALGB
9344. Proceedings of the American Society of Clinical Oncology, 24(18S, I of II):5s, #510, 2006.
104. Ambrosone CB, Barlow W , Yeh I-T, Hayes DF, Davis W , Rae JM, Hutchins LF, Livingston R, Ravdin P,
Martino S, Osborne K, Abeloff M, Lyss AP, Albain K.. Pharmacogenetics and breast cancer treatment
outcomes: results on oxidative stress-related genotypes (MPO, MnSOD) from a southwest oncology group
intergroup trial (INT-0102). Breast Cancer Research and Treatment (29th Annual San Antonio Breast Cancer
Symposium). 100(1):S18, #37, 2006
105. Hershman D, Unger J, Barlow W , Hutchins L, Martino S, Abeloff M, Norton L, Livingston R, Osborne K,
Albain K, Treatment quality and outcome of African American vs. European American Breast Cancer
Patients: Retrospective Analysis of Southwest Oncology Group Studies S8814/S8897. Breast Cancer
Research and Treatment (29th Annual San Antonio Breast Cancer Symposium) 100(1):,S140, #3049;2006.
Silvana Martino, D.O.
Curriculum Vitae
Page 26
106. Muss HB, Tu D, Ingle JN, Martino S, Robert NJ, Pater JL, W helan T, Palmer MJ, Piccart MJ, Shapher LE,
Prithcard KI, He Z, Goss PE. The benefits of letrozole in postmenopausal women with early stage breast
cancer who have had five years of tamoxifen are independent of age. Breast Cancer Research and
Treatment (29th Annual San Antonio Breast Cancer Symposium). 100(1):S23, #102, 2006.
107. Perez EA, Romond EH, Suman VJ, Jeong J, Davidson NE, Geyer CE, Martino S, Mamounas EP, Kauffman
PA, W olmark N. Updated Results of the comnined analysis of NCCTG N9831 and NSABP B-31 adjuvant
chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer. Journal of Clinical
Oncology 2007: 25(18S): 6S#512
108. Sparano J.A., W ang M., Martino S., Jones V., Perez E., Saphner T., W olff A,C., Sledge G.W . Jr, W ood
W .C., Davidson N.E.. Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel
given every 3 weeks or weekly in operable breast cancer: Results of Intergroup Trial E1199. Journal of
Clinical Oncology 2007; 25(18S): 6S #516
109. Kutteh LA, Hobday T, Jaffe A, LaPlant B, Hillman D, Kaufman P, Davidson N, Martino S, Moreno A, Perez
E. A correlative study of cardiac biomarkers and left ventricular ejection fraction (LVEF) from N9831, a phase
III randomized trial of chemotherapy and trastuzumab as adjuvant therapy for HER-2 positive breast cancer.
Journal of Clinical Oncology 2007: 25(18S): 6S #579
110. Slovak ML, Bedell V, Lew D, Albain KS, Ellis GK, Livingston R, Martino S, Perez E, Sher D, Stock W .
Screening for clonal hematopoiesis as a predictive marker for development of t-AML following adjuvant
therapy for breast cancer (S0012). Journal of Clinical Oncology 2007: 25(18S): 598s #11051
111. Moreno-Aspitia, Dueck A, Lingle W , Kutteh K, Tenner N, Davidson S, Martino S, Kaufman W P, Carney E,
Perez E. Serum HER2 (sHER2) levels in early stage HER@ neu (+) breast cancer (HER2+BC). Results
from NCCTG adjuvant Intergrioup trial N9831. Journal of Clinical Oncology 2008; 26: # 529.
112. Perez EA, Reinholz MM, Dueck AC, W iktor AE, W ilma LL, Nancy ED, Martino S, Kaufman PA, Kutteh LA &
Jenkins RB. c-MYC (MYC) amplification and correlation with patient outcome in early stage HER2+ breast
cancer (BC) from the NCCTG adjvant Intergroup trial N9831. Cancer Res, 2008; 69(Suppl.): (2) Abstract
#56.
113. Sparano JA, Gray R, Goldstein LJ, Childs BH, Bugarini R, Rowley S, Baker J, Shak S, Badve S, Baehner FL,
Perez E, Shulman LN, Martino S, Sledge GW , Davidson NE. Grb7-Dependent Pathways are Potential
Therapeutic Targets in Triple Negative Breast Cancer. Cancer Res, 2008; 69(Suppl.): (2) Abstract #25.
114. W R Sukov, DV Miller, AC Dueck, KS Tenner, RB Jenkins, NE Davidson, PA Kaufman, S Martino, SR
Dakhil, V Roy, EA Perez. Breast Tumors with Focal HER2 Amplified Clones Show Similar Response to
Trastuxzumab Therapy as Diffusely HER2 Amplified Breast Tumors; Data from NCCTG N9831 Intergroup
Adjuvant Trial. J Clin Oncol 27:15s, 2009 (suppl; abstr 520)
115. J.A. Sparano, R. Gray, L.J.Goldstein, B.H. Childs, D. Brassard, R. Bugarini, S. Rowley, J.Baker, S. Shak,
S.Badve, F.L. Baehner, , P. Kenny, E. Perez, L.N. Shulman, S. Martino, G.W .Sledge, Jr., and N.E.
Davidson. Gene Expression Profiling of Phenotypically-Defined Hormone-Receptor Positive Breast Cancer:
Evidence for Increased Transcriptional Activity of the Insulin Growth Factor Receptor Pathway and Other
Pathways (Submitted June 2009 to SABCS 2009)
116. JA Sparano, M W ang, V Stearns, S Martino, V Jones, EA Perez, T Saphner, AC W olff, GW . Sledge Jr., W C
W ood, and NE. Davidson. Black race is associated with a worse outcome in patients with hormone receptor
positive, HER2-normal breast cancer treated with adjuvant chemohormonal therapy. (Submitted June 2009
to SABCS 2009)
117. Monica M Reinholz, Amylou C Dueck, Anne E W iktor, W ilma L Lingle, Robert B Jenkins, Nancy E Davidson,
Silvana Martino, Peter A Kaufman, Leila A Kutteh, George W Sledge, Lyndsay N Harris, Julie R Gralow,
Xochiquetzal Geiger, Edith A Perez. c-MYC (MYC) protein expression and associations with trastuzumab
benefit in early-stage, HER2+ breast cancer in context of the NCCTG adjuvant trial, N9831. (Submitted June
2010 to San Antonio Breast Cancer Symposium)
Silvana Martino, D.O.
Curriculum Vitae
Page 27
118. Ravdin P, Martino S, Pegram M, Robert N, Swain S, Janssen D, Bowser A, Mortimer J, Carlson R.
Utilization and clinical practice impact of an interactive tool for guiding choice of systemic adjuvant treatment
for patients with early breast cancer. J Clin Oncol 29:15s, 2011 (abstr 6063)
119. Perez E, DueckA, Reinholz M, Chen B, Geiger X, Jenkins R, Lingle W , Andorfer C, Davidson N, Martino S,
Kaufman P, Kutteh L, Sledge G, Harris L, Gralow J, McCullough A. Effect of PTEN protein expression on
benefit to adjuvant trastuzumab in early-stage HER2+ breast cancer in NCCTG adjuvant trial N9831. J Clin
Oncol 29:15s, 2011 (abstr10504)
120. Reinholtz M, Martino S, et al. Effect of IGF1R protein expression on benefit to adjuvant trastuzumab in
early-stage HER2+ breast cancer in NCCTG N9831 trial. J Clin Oncol 29:15s, 2011 (abstr 10503)
121. Schneider B, W ang M, Stearns V, Martino S, JonesV, Perez E, Saphner T, W olff A, Sledge G, W ood W ,
Davdson N, Sparano J. Relationship between taxane induced neuropathy and clinical outcomes after
adjuvant chemotherapy. Breast Cancer Symposium 2011 Proceedings,2011, (abstr 270)
122. Romond E H, Suman V J, Jeong J-H, Sledge G, Geyer Jr CE, Rastogi P, Gralow J, Martino S, Swain S M,
W iner E, Colon-Otero G, Zujewski J, Paik S, Mamounas E, W olmark N, Perez E A. Trastuzumab Plus
Adjuvant Chemotherapy for HER2-Positive Breast Cancer: Final Planned Joint Analysis of Overall Survival
(OS) from NSABP B-31 and NCCTG N9831. (submitted to San Antonio Breast Symposium, 2012)
PRESENTATIONS:
Invited and/or Refereed Internationally or Nationally:
1.
Martino S, Ownby H, Russo J, Roi L, Brennen MJ. "Interrupted Pregnancy as an Indicator of Prognosis in
Primary Breast Cancer". 5th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas,
November 5-6, 1982.
2.
Martino S. "Therapy of Breast Cancer". The 9th Annual Modern Oncology for General Practitioners,
(sponsored by American Cancer Society and the Florida Osteopathic Medical Association), Ft. Lauderdale,
Florida, September 6-7, 1984.
3.
Martino S. "Breast Cancer". "The Science of Aging". American College of Osteopathic Internists, 44th
Annual Convention and Scientific Sessions, Lake Buena Vista, Florida, October 14-19, 1984.
4.
Schilcher RB, Decker D, Evans LJ, Martino S, Kresge C, Young JD, Samal, B.A., Singhakowinta, A.
"Influence of Age on Pharmacokinetics of 5-Fluorouracil (5FU)." 7th Annual Breast Cancer Symposium,
December 7-8, 1984, San Antonio, Texas.
5.
Martino, S., Ratanatharathorn, V., Karanes, C., Samal, B.A., Sohn, Y.S., Rudnick, S.E. "Reversible
Arrhythmias Observed in Patients Treated with Recombinant DNA-Alpha 2 Interferon." 7th Annual San
Antonio Breast Cancer Symposium, December 7-8, 1984, San Antonio, Texas.
6.
Martino, S., Schilcher, R.B., Marier, S.J., Evans, L.F., Allen, B.J., Young, J.D. "Clinical and Pharmacokinetic
Results in a Breast Cancer Patient with Hyperbilirubinemia Treated with Doxorubicin (DOX)." 7th Annual
Breast Cancer Symposium, December 7-8, 1984, San Antonio, Texas.
Silvana Martino, D.O.
Curriculum Vitae
Page 28
7.
Martino, S. "4`Deoxydoxorubicin as First Line Therapy for Metastatic Breast Cancer". 8th Annual San
Antonio Breast Cancer Symposium, November 7-8, 1985, San Antonio, Texas.
8.
Martino, S. "Ovarian Function with use of LHRH Agonists in W omen with Breast Cancer." Developmental
Therapeutics Symposium. SW OG meeting February 23, 1986, San Antonio, Texas.
9.
Martino, S. "Cancer of the Breast: Radical Mastectomy vs. Lumpectomy; The Role of Mammography".
Fourth Annual Joint Session of the American Osteopathic Association and Upjohn Company, November 6,
1986, Las Vegas, Nevada.
10. Martino, S. "4 Nitroestrone-3 Methyl Ether". Development Therapeutics Symposium SW OG meeting,
Columbus, Ohio, September, 15-17, 1987.
11. Martino, S. "Chemotherapy of Breast Cancer". American College of Physician's Postgraduate Course,
Medical Oncology Board Review Course, Columbus, Ohio, September 15-17, 1987.
12. Martino, S. "A Breast Cancer Prevention Trial - Clinical and Scientific Studies" at Experimental
Therapeutics Symposium, SWOG. October 24, 1988.
13. Flaherty, L., Redman, B., Martino, S., Valdivieso, M., Rudolph, A. "Sequential recombinant interleukin-2
(rIL-2) and dacarbazine (DTIC) (RID-1) in metastatic malignant melanoma (MMM) clinical and immunologic
results". Society for Biological Therapy, November 6-11, 1988.
14. Redman, B., Flaherty, L., Chou, T.H., Martino, S., Al-Katib, A., Kaplan, J., Valdivieso, M. "Phase I trial of
combination therapy with recombinant interleukin-2 (IL-2) and recombinant interferon-gamma (IFN- ) in
patients with cancer". Society for Biological Therapy, November 6-11, 1988.
15. Martino, S., Gala, R., Valeriote, F., Kim, P., Heilbrun, L., Kresge, C., Boomer, A. "Prolactin as a predictor of
breast cancer risk". 11th Annual San Antonio Breast Cancer Symposium, Texas, November 29-30, 1988.
16. Ensley, J., An, T., Martino, S., W eaver, D., Benitez, P., Valeriote, F., Heilbrun, L. "Flow cytometry and
cytology from fine needle aspirates of breasts from women at high risk for breast cancer". 11th Annual San
Antonio Breast Cancer Symposium, Texas, November 29-30, 1988.
17. Martino, S., Gala, R., Valeriote, F., Kim, P., Heilbrun, L., Kresge, C., Boomer, A. "Prolactin as a predictor of
breast cancer risk". 11th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, November
29-30, 1988.
18. Martino, S. "Research In Breast Cancer Prevention". Presented at W omen Physicians on Medical Issues,
Ohio University College of Osteopathic Medicine, Athens, Ohio, April 1, 1989.
19. Martino, S., Ensley, J., W eaver, D., Benitez, P., An, T., Maciorowski, Z., deBraud, F., Hassan, M.,
KuKuruga, M., Singhakowinta, A., Valeriote, F. "Cellular DNA content characteristics of needle aspirates
from patients at high risk for developing breast cancer". American Association for Cancer Research, San
Francisco, California, May 24-27, 1989.
20. Martino, S. "The Oncologist's Role in Breast Cancer". The American Osteograthic College of Radiology
Meeting, Chicago, June 1989.
21. Martino, S. "Diet and Breast Cancer Prevention". The American Osteograthic College of Radiology
Meeting, Chicago, June 1989.
22. Boomer, A., Martino, S., Krag, G., Liang, D., Bacus, J., Reading, B., Heilbrun, L. "Compliance to a 15% fat
diet in women at risk for breast cancer". 12th Annual San Antonio Breast Cancer Symposium. San Antonio,
Texas, December, 1989.
23. Flaherty, L., Robinson, W ., Redman, B., Gonzales, R., Martino, S., Kraut, M., Valdivieso, M. and Rudolph, A.
"A phase I study of dacarbazine (DTIC), cisplatin (DDP), and outpatient interleukin-2 (IL-2) (RIDD-2) in
metastatic malignant melanoma (M.M.M.)". ASCO, W ashington, D.C., May, 1990.
Silvana Martino, D.O.
Curriculum Vitae
Page 29
24. Martino, S. "Coagulation effects and thrombophlebitis of Tamoxifen". Presented at the Tamoxifen Health
Trial Network Meeting, Madison, W isconsin. Sponsored by the University of W isconsin Clinical Cancer
Center. June, 1990.
25. Martino, S. "Breast cancer prevention with Tamoxifen". Presented to SW OG Breast Committee Scientific
Session, Columbus, Ohio, October 3, 1990.
26. Lemanne, D., Simon, M., Martino, S., Swanson, M. "Breast carcinoma in situ (CIS): Greater rise in ductal
carcinoma in situ (DCIS) vs. lobular carcinoma in situ (LCIS)". ASCO, Houston, TX, March 1991.
27. Chlebowski, R.T., Rose, D., Blackburn, G., Buzzard, M., Khandekar, J., York, R., Insull, W ., S., Martino,
Elashoff, R., W ynder, E. Feasibility of using dietary fat intake reduction in adjuvant breast cancer
management. ASCO Houston, TX, March 1991.
28. Redman, B., Flaherty, L., Chou, T.H., Kraut, M., Martino, S., Simon, M., Groves, E. Phase I trial of
recombinant macrophage-colony stimulating factor (M-CSF) by rapid intravenous (IV) infusion in patients
with cancer. ASCO, Houston, TX, March 1991.
29. Simon, M., Schwartz, A., Martino, S., Swanson, M. Trends in the diagnosis of in situ breast cancer in the
Detroit Metropolitan Area. ASCO, Houston, TX, March 1991.
30. Kraut, M., W ozniak, A., Flaherty, L., Redman, B., Samal, B., Martino, S., Simon, M., Valdivieso, M.
Treatment of metastatic non-small cell lung cancer (NSCLC) with mitomycin, etoposide, and cisplatin (MEP).
ASCO, Houston, TX, March 1991.
31. Simon, M., Lemanne, D., Martino, S., Schwartz, A., Swanson, G.M. Trends in the incidence of in situ and
invasive breast cancer in the Detroit Metropolitan Area. 14th Annual San Antonio Breast Cancer
Symposium, San Antonio, TX, December 6-7, 1991.
32. Ensley, J., W eaver, D., Benitez, P., An, T., Maciorowski, Z., Alonso, M., Kukuruga, M., Martino, S. Dietary
modulation of abnormal DNA histograms from breast aspirates of women at high risk for developing breast
cancer. First International Cancer Molecular Biology Symposium, Cairo, Egypt, December 1-3, 1992.
33. Djuric, Z., Simon, M.S., Luongo, D.A., LoRusso, P.M. & Martino, S. Levels of 5-hydroxymethyl-2'deoxyuridine in blood DNA as a marker of breast cancer risk. American Association of Cancer Research,
April 1994, San Francisco.
34. A. Lichter, S. Green, K. Albain, L. Hutchins, S. Martino. The Influence of Patient Characteristics,
Socioeconomic (SES) Factors, Geography, and Systemic Risk on the Use of Breast Sparing Treatment in
the Adjuvant Breast Cancer Studies. ASCO meeting, May 14-17,1994, Dallas, TX.
35. Taylor CW , Green S, Dalton W S, Martino S, Ingle JN, Robert NJ, Rector DJ, Osborne CK, (and
Participating Investigators of the Southwest Oncology Group, North Central Cancer Treatment Group and
Eastern Cooperative Oncology Group). A Multi-Center Randomized Trial of Zoladex Versus Surgical
Ovariectomy in Pre-Menopausal Patients with Receptor Positive Metastatic Breast Cancer. 18th Annual San
Antonio Breast Cancer Symposium, December 8-13, 1995, San Antonio, TX.
36. Taylor CW , Green S, Dalton W S, Martino S, Ingle JN, Robert NJ, Osborne CK (and Participating
Investigators of the Southwest Oncology Group, North Central Cancer Treatment Group and Eastern
Cooperative Oncology Group). Phase 3, Randomized, Multi-Center Comparison of Zoladex Versus Surgical
Ovariectomy in Premenopausal Patients with Receptor Positive Metastatic Breast Cancer (to be presented at
the Sixth International Congress on Anti-Cancer Treatment, February 6-9, 1996, Palais Des Congres, Paris,
France)
37. Martino, S. Adjuvant Therapy of Breast Cancer, Allen Zieger Memorial Lecture Series. Botsford Hospital,
Farmington, Michigan, October, 1997.
38. Martino, S. “Breast Cancer Prevention”, Sponsored by SW OG Cancer Control Committee, SW OG meeting,
April 1998.
Silvana Martino, D.O.
Curriculum Vitae
Page 30
39. Martino, S. “Breast Cancer update Sponsored by Bristol Myer-Squibb, Data Managers Educational
Synposium, St. Louis, Missouri. June 1998.
40. Martino, S. LHRH Agonists Sponsored by Zeneca Pharmaceuticals, Speaker Bureau Training Program,
W est Palm Beach, Florida. June 1998.
41. Martino, S. Management of Metastatic Disease and Controversies in Breast Cancer, presented at Medical
Oncology of Breast Cancer Fellows Program, Sponsored by University of Texas, M.D. Anderson Cancer
Center, July 1998.
42. Martino, S. New Developments in Adjuvant Management of Breast Cancer, presented to Piedmont
Oncology Association, 19th Annual Symposium, Sponsored by W ake Forest University, October 1998.
43. Martino, S. “Latest Data on the use of Tamoxifen in Treatment”, presented at Breast Cancer Speakers
Update - Zeneca Pharmaceutical – Scottsdale, AZ, April 9-10, 1999.
44. Martino, S. “Metastatic Therapy – Treatment”, presented at the Medical Oncology of Breast Cancer Fellows
Program – Sponsored by University of Texas, M.D. Anderson Cancer Center, July 1999.
45. Martino, S. “Breast Cancer Therapy – Approaching the New Millennium” – Sponsored by Network for
Medical Communication & Research. W ashington, DC., May 6, 2000.
46. Martino, S. “High Dose Chemotherapy”, presented at ASCO, Poster Discussion Session. New Orleans,
Lousiana, May 22, 2000.
47. Martino, S. “Metastatic Breast Cancer – The Role of Gemzar” Sponsored by Network for Medical
Communication & Research. Englewood, CO., August 25 – 26, 2000.
48. Noe LN, Becker RV, Gore M, Martino S, Eiremann W , Namer M, Howell T, Bianco AR, W antanabe T, Chen
DM, “An Approach to Designing a Multi-National Model for the Current Treatment of Breast Cancer”. Poster
Presentation, ISPOR Third Annual European Conference. Antwerp, Belgium. November 5 – 7, 2000.
49. Martino, S. “NOCR’s 2001 ASCO Highlights Program” Sponsored by Network for Medical Communications
and Research. Las Vegas, NV. June 22-23, 2001.
50. Martino, S. “NOCR’s 2001 ASCO Highlights Program” Sponsored by Network for Medical Communications
and Research, Delray Beach, FL. June 29-30, 2001
51. Martino, S. ”Challenging Cases in Patient Management” Sponsored by Network for Medical Communication
and Research, Las Vegas, NV. September 8, 2001.
52. Martino, S. “A Phase III Trial of Taxol (T)/Doxorubicin/Cytoxan (D) (Two Dose Levels) Versus
Doxorubicin/Cytoxan (C) Followed by a Comparison of W eekly Versus Q3 W eekly T in Patients (pts) with
Metastatic Breast Cancer (MBC”). Presented at ASCO Poster Discussion, Orlando, FL, May 18-21, 2002.
53. McNabb M, Martino S, Secrest RJ, Bryant K, Blatter J, Powles T, Mershon J, “Baseline Breast Cancer Risk
Demographics and Methodology for the Raloxifene Use for The Heart (RUTH) and Continuing Outcomes
Relevant to Evista (CORE) Studies, Two Breast Cancer Prevention Trials”. Presented at the 13th
International Meeting of The European Society of Gynecologic Oncology, Brussels, April 8, 2003.
54. Albain KS, Unger JM, Hutchins LF, Rivkin SE, Martino S, Livingston RB, Osborne CK. “Outcome of African
Amercans on Southwest Oncology Group (SW OG) breast cancer adjuvant therapy trials”. Presented at the
26th Annual San Antonio Breast Cancer Symposium, December 3-6, 2003.
55. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pater
JL. Randomized placebo-controlled trial of letrozole in postmenopausal women with early breast cancer
completing five years of tamoxifen. Presented at the 26th Annual San Antonio Breast Cancer Symposium,
December 3-6, 2003.
Silvana Martino, D.O.
Curriculum Vitae
Page 31
56. Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon JL, Disch D, Secrest RJ, Cummings SR.
Incidence of invasive breast cancer following 8 years of raloxifene therapy in postmenopausal women with
osteoporosis: Results from the Continuing Outcomes Relevant to Evista (CORE) trial. ASCO Oral
Presentation, New Orleans, LA, June 5-8, 2004.
57. Cauley JA, Martino S, Barrett-Connor E, Powles TJ, Mershon JL, Disch D, Secrest RJ, Cummings SR.
Effect of raloxifene on invasive breast cancer incidence in postmenopausal women stratified by Gail risk
assessment: Results of the Continuing Outcomes of Relevant to Evista® (CORE) trial. ASCO General
Poster Session, New Orleans, LA, June 5-8, 2004.
58. Martino S, Powles T, Cauley J, Mershon J, Disch D, Secrest R, Cummings S. Effect of raloxifene on
incidence of invasive breast cancer in postmenopausal women stratified by baseline serum estradiol:
Results of the Continuing Outcomes Relevant to Evista® trial. 26th San Antonio Breast Cancer Symposium,
Abstracts – General Oral Session, December 8-11, 2004.
59. Martino S, Disch D, Dowsett S, Mershon J. Raloxifene and breast cancer risk reduction based on breast
cancer family history. The American College of Obstetrics and Gynecology 53rd Annual Clinical Meeting Oral
Presentation, San Francisco, CA, May 7–11, 2005.
60. Martino S, Disch D, Dowsett S, Mershon J. Effect of raloxifene on invasive breast cancer incidence in
postmenopausal women stratified by age (<65 and >65 years). ASCO General Poster Session, Orlando, FL,
May 13–17, 2005.
61. Perez EA, Suman VJ, Davidson N, Martino S, Kaufman P. NCCTG N9831 (Presenter: Perez EA) ASCO
Education Session: Advances in Monoclonal Antibody Therapy for Breast Cancer, Orlando, FL, May 13–17,
2005.
62. Romond EH, Perez EA, Bryant J, Suman V, Geyer CE, Davidson N, Tan-Chiu E, Martino S, Swain SM,
Kaufman P, Feherenbacher L, Pisansky T, Vogel V, Kutteh LA, Yothers G, Visscher D, Brown AM, Jenkins
R, Seay TE, Mamounas E, Abrams J, W olmark N. Doxorubicin and cyclophosphamide follwed by paclitaxel
with or with0ut trastuzumab as adjuvant therapy for patients with HER-2 positive operable breast cancer.
Combined analysis of NSABP-B31/NCCTG-N9831. (Presenter: Romond EH) ASCO Education Session:
Advances in Monoclonal Antibody Therapy for Breast Cancer, Orlando, FL, May 13–17, 2005.
63. Martino S. Breast Cancer Research. ACOI: 67th Annual Convention and Scientific Sessions
October 10-14, 2007, Boston, MA
64. Martino S. Decreasing the Continued Risk of Recurrence: Extended Adjuvant Endocrine Therapy Update.
Novartis: US Speaker Update Meeting, San Francisco, CA, July 17, 2008.
65. Martino S. “Magnetic Resonance Imaging (MRI) for the Diagnosis and Staging of Breast Cancer”, American
College of Osteopathic Internists (ACOI) 68th Annual Convention and Scientific Sessions, Marco Island, FL,
November 1, 2008.
66. Martino S. “Breast Cancer: Trial Updates & Current Recommendations” 2009 Annual Clinical Assembly of
Osteopathic Surgeons. Chicago, IL, November 1, 2009.
Invited and/or Refereed Locally/Regionally:
1.
Martino, S. "Systemic Therapy of Advanced Breast Cancer". Michigan State University Life-Long Education
Programs, Breast Cancer Conference, Lansing, Michigan, April 1981.
2.
Martino, S. "Breast and Female Reproductive Organs". Michigan Cancer Foundation, Public Response
Program, Volunteer Training Program, Detroit, Michigan, October 1981.
3.
Martino, S. "Side Effects of Chemotherapy". Michigan Cancer Foundation, Cancer Awareness Forum for
Volunteers, Detroit, Michigan, October 29, 1981.
Silvana Martino, D.O.
Curriculum Vitae
Page 32
4.
Martino, S. "Breast Cancer and Female Reproductive Cancers". Michigan Cancer Foundation, Cancer
Information Service of Michigan, Detroit, Michigan, April 21, 1982.
5.
Martino, S. "Breast Cancer". American Cancer Society, Reach to Recovery Program, W arren, Michigan,
June 2, 1982.
6.
Martino, S. "Approach to the Breast Mass and Current Treatment of Breast Carcinoma". Sinai Hospital,
Detroit, Michigan, October 1982.
7.
Martino, S. "Breast Cancer". American Cancer Society, Reach to Recovery Program, W arren, Michigan,
November 10, 1982.
8.
Martino, S. "The Selection of Therapy for Metastatic Disease in Breast Cancer. Update-Breast Cancer".
Flint Osteopathic Hospital, Earl E. Congdon, D.O., Lecture Series, February 16, 1983.
9.
Martino, S. "Breast Cancer Symposium: Potentially Curable Breast Cancer". Michigan Association of
Osteopathic Physicians and Surgeons, Inc. 84th Annual Postgraduate Conference and Scientific Seminar,
Dearborn, Michigan, May 19, 1983.
10. Martino, S. "Breast Cancer and Approach to the Breast Mass". Sinai Hospital Housestaff, Sinai Hospital of
Detroit, Michigan, September 9, 1983.
11. Martino, S. "Breast Cancer". American Association of University W omen, Grosse Pointe Branch, Grosse
Pointe, Michigan, November 1983.
12. Martino, S. "Breast Cancer". Riverside Osteopathic Hospital, Trenton, Michigan.
Laboratories, Inc., December 5, l983.
Sponsored by Adria
13. Martino, S. "Breast Cancer". Hutzel Hospital Grand Rounds, Detroit, Michigan, February 9, l984.
14. Martino, S. "Breast Cancer and Cancers of the Female Reproductive System".
Foundation-Cancer Information Service, Volunteer Training Program, April 10, 1984.
Michigan Cancer
15. Martino, S. "Breast Cancer-Part II". Riverside Osteopathic Hospital, Trenton, Michigan, May 14, 1984.
Sponsored by Adria Labs Inc.
16. Martino, S "The Emotional and Physical Adjustment of Having a Mastectomy". American Cancer Society`s
Reach to Recovery Program, W arren, Michigan, June 6, 1984.
17. Martino, S. "Cancer Awareness". Charles A. Zackary Memorial Lecture, Michigan Cancer Foundation,
August 2, 1984.
18. Martino, S. "Plain Talks about Breast Cancer". Harper-Grace Hospitals, Community Health Programming,
Southfield Civic Center, October 23, 1984.
19. Martino, S. "Breast Cancer - Reducing Your Risk." Strategies `85. Cobo Hall, March 15, 1985, Detroit,
Michigan.
20. Martino, S. "Breast Cancer". Sponsored by Binson's Medical Supplies, May 4, 1985, Holiday Inn, W arren,
MI.
21. Martino, S. "The Emotional and Physical Adjustment of Having a Mastectomy". American Cancer Society,
May 29, 1985, Christ Lutheran Church, W arren, MI.
22. Martino, S. "Chemotherapy of Advanced Disease". American College of Physicians Postgraduate Course,
Medical Oncology-Principles of Patient Management, September 7-10, 1985, W estin Hotel, Detroit, MI.
23. Martino, S. "Physical and Emotional Adjustment to Mastectomy". American Cancer Society, April 4, 1986,
Port Huron, MI.
24. Martino, S. "Breast Cancer". Binson's Hospital Supplies, April 12, 1986, Detroit, MI.
Silvana Martino, D.O.
Curriculum Vitae
Page 33
25. Martino, S. "Management of Breast Cancer". Michigan Cancer Foundation, Breast Cancer Detection Center
Program. June 6, 1986, Detroit, MI.
26. Martino, S. "Sexual Dysfuntion of Breast Cancer". Michigan State Medical Society 1986 Annual Scientific
Meeting, November 12, 1986, Dearborn, MI.
27. Martino, S. "Management of W omen at High Risk for Developing Breast Cancer". Michigan State Medical
Society 1986 Annual Scientific Meeting, November 13, 1986.
28. Martino, S. "Emotional and Physical Adjustment of Having a Mastectomy". American Cancer Society,
Michigan Division, February 13, 1987, Marysville, MI.
29. Martino, S. "Dietary Intervention in W omen at High Risk for Breast Cancer". Hutzel Hospital, March 19,
1987, Detroit, MI.
30. Martino, S. "National History of Breast Cancer". Breast Cancer Symposium sponsored by the Federal
W omens Program U.S. Food & Drug Administration, Detroit, MI. May 27, 1987.
31. Martino, S. "Breast Cancer". Presented at The Third Annual Breast Surgery Awareness Day sponsored by
Binson's Hospital Supplies Co. Detroit, MI. June 6, 1987.
32. Martino, S. "Breast Cancer Management". Presented at the 1987 Research for Recovery Semimar,
sponsored by the American Cancer Society, W arren MI.
33. Martino, S. "W orkshop - Controversial Topics in Early Breast Cancer". Presented at W ayne State
University/Detroit Medical Center Department of Internal Medicine Medical Grand Rounds at Harper Hospital,
Detroit, MI, April 6, 1988.
34. Martino, S. "Oncology Prespectives". The W omen Physicians on Medical Issues, College of Osteopathic
Medicine, Ohio University, April 23, 1988.
35. Martino, S.
"Breast Cancer Management".
The Cancer Information Service, Meyer L. Prentis
Comprehensive Cancer Center of Metropolitan Detroit, June 7, 1988.
36. Martino, S. "The Management of Breast Cancer". Internal Medicine Grand Rounds, Bi-County Community
Hospital, May 13, 1988.
37. Martino, S. "Breast Cancer Prevention".
November 2, 1988.
Research Division Meeting, Michigan Cancer Foundation,
38. Martino, S. "Breast Cancer Prevention Program", Ford Motor W omen's Club, Dearborn, MI, November 10,
1988.
39. Martino, S. "Breast Cancer Prevention". Presented May 13, 1990 at Breast Cancer: Results of the 80's
outlook for the 90's. The Allen Zieger D.O. Memorial Lecture Series, Botsford Hospital, Farmington,
Michigan. Sponsored by the ACS.
40. Martino, S. "Breast Surgery Update". Botsford General Hospital, Farmington, Michigan, Department of
Surgery, Surgery Updates Series, March 5, 1991.
41. Martino, S. "Breast Cancer: Current Research". The Margaret L. King Lecture, Sponsored by the Detroit
Dietetic Association, Oakwood Hospital, Dearborn, Michigan, April 10, 1991.
42. Martino, S. "Breast and Cervical Cancer". Urban Medicine Symposium, W ayne State University School of
Medicine, Department of Family Medicine, Michigan Health Center and the Detroit Health Department, Hotel
St. Regis, Detroit, Michigan, September 8, 1991.
43. Martino, S. "Breast Cancer Prevention". Volunteer Leadership Recognition Day.
Foundation, Detroit, Michigan, September 24, 1991.
Michigan Cancer
Silvana Martino, D.O.
Curriculum Vitae
Page 34
44. Martino, S. "Diet and Breast Cancer Prevention". Cancer Loan Closet Foundation, Harper Hospital, Detroit,
Michigan, March 24, 1992.
45. Martino, S. "Prevention of Breast Cancer". Internal Medicine Grand Rounds, Harper Hospital, Detroit,
Michigan, March 25, 1992.
46.
Martino, S. "Diet and Breast Cancer Prevention". The Michigan Leadership Summit: The challenge of
breast cancer, Hutzel Conference Center, Detroit, Michigan, April 10, 1992.
47.
Martino, S. "Breast Cancer Update." Reach to Recovery, Camarillo Chapter, Sponsored by AM. Cancer
Soc. Camarillo, CA, February 5, 1994.
48.
Martino, S. “Breast Cancer Update” Reach to Recovery, Thousand Oaks Chapter, Sponsored by AM.
Cancer Soc., Thousand Oaks, CA, April 1998.
49.
Martino, S. “Tumor Board on Lobular Carcinoma”, Queen of Angels Hospital, Sponsored by Los Angeles
Radiological Society, Hollywood, CA, May 1998.
50.
Martino, S. “Breast Cancer” presented at the AAUW W omen’s Health Forum, Cancer: W hat W omen need
to know, sponosored by the American Association of University W omen, Thousand Oak, CA, January 30,
1999.
51.
Martino, S. “Treatment of Metastatic Breast Cancer” Breast Cancer: Comprehensive Management 1999,
CME program for Mount Carmel Health System, Columbus, OH, March 19, 1999.
52.
Martino, S. “Breast Cancer Update” sponsored by The W ellness Community, W estlake Village, CA, June
17, 1999.
53.
Martino, S. “New Directions in Cancer Treatment 99”, sponsored by Institute for Continuing Healthcare
Education, American Cancer Society and UC Davis Cancer Center, Sacramento, CA, June 19, 1999.
54.
Martino, S. “Update on Adjuvant Therapy of Breast Cancer” CME program for St. John’s Health Center,
Santa Monica, CA, August 5, 1999.
55.
Martino, S. “Breast Cancer: W hat’s New in Diagnosis, Treatment and on the Horizon”, sponsored by The
W ellness Community, Santa Monica, CA, August 28, 1999.
56.
Martino, S. “Current Issues in Adjuvant Treatment”, Summit on Cancer in W omen, W ayne State University
School of Medicine. Detriot, MI, September 24, 1999.
57.
Martino, S. “Controversies in the Multi Modality Treatment of Breast Cancer”, Sponsored by The Genesys
Hurley Cancer Institute and Bristol Myer Squibb. Flint, MI, October 13, 1999.
58.
Martino, S. “New Developments and Future Trends in the Treatment of Breast Cancer”, Clinical Research
Associate Plenary Session, Southwest Oncology Group, San Diego, CA, October 21, 1999.
59.
Martino, S. “Update in Breast Cancer”, Presented at “Update in Oncology”, Sponsored by Scripps Clinic, La
Jolla, CA, November 5, 1999.
60.
Martino, S. “Breast Cancer: W hat’s New in Diagnosis, Treatment and on the Horizon” sponsored by The
W ellness Community, Santa Monica, CA, January 8, 2000.
61.
Martino, S. “Update in Breast Cancer”, Presented at After Breast Cancer Group, Los Robles Hospital, East
Campus, W estlake Village, CA, February 3, 2000.
62.
Martino, S. “Cancer Updates”, Presented at Reach to Recovery Recertification (Continuing Volunteer
Education), Ventura County Units, American Cancer Society, Ventura, CA, March 25, 2000.
Silvana Martino, D.O.
Curriculum Vitae
Page 35
63.
Martino, S. “New Developments and Future Trends in the Treatment of Breast Cancer” presented at The
W anda J. Cobb Breast Health Symposium, sponsored by High Priority and The Susan G. Komen
Foundation, Newport Beach, CA, April 1, 2000.
64.
Martino, S. “New Hormonal Therapy of Breast Cancer” sponsored by Novartis Oncology, Los Angeles, CA.,
March 27-28, 2001.
65.
Martino, S. “New Approaches in the Treatment of Early Stage Breast Cancer” sponsored by OrthoBiotech
Oncology, Orange, CA, August 21, 2001.
66.
Martino, S. “Adjuvant Therapy of Breast Cancer, sponsored by Eli Lilly, Cottage Hospital, Santa Barbara,
CA, November 6, 2001.
67.
Martino, S. “Breast Cancer Update”, Festival of Hope – Guest Speaker – Ronald Reagan Presidential
Library, Moorpark, CA, August 16, 2002.
68.
Martino, S. “Breast Cancer Update”, sponsored by The W ellness Community, W estlake Village, CA,
October 15, 2002.
69.
Martino, S. “Breast Cancer Update”, sponsored by The W estlake Village ABC Meeting, W estlake Village,
CA, November 7, 2002.
70.
Martino, S. “Breast Cancer 101”, sponsored by High Priority, The Breast Cancer Information Network for
The W anda J. Cobb Breast Health Symposium, Irvine, CA, April 5, 2003.
71.
Martino, S. “Let’s Talk Breast Cancer”, sponsored by The W ellness Community, W estlake Village, CA,
October 21, 2003.
72.
Martino, S. “Metastatic Breast Cancer”, presented at the John W ayne Cancer Institute Professor
Lectureship (in conjuction with Pre-op and Fellows Conference), Santa Monica, CA, April 9, 2004.
73.
Martino, S. “Breast Cancer Diagnosis, Prognosis and Treatment: An Overview”, presented at the 72nd
Annual Meeting of the American Society for Clinical Laboratory Science / Clinical Science Investigation: Los
Angeles, CA, July 26, 2004.
74.
Martino, S. “ASCO Update”, presented at the John W ayne Cancer Institute Breast and Endocrine Meeting,
Santa Monica, CA, August 10, 2004.
75.
Martino, S. “Return to W ellness: A New Beginning After Breast Cancer Treatment”, sponsored by The
W ellness Community, W estlake Village, CA, October 18, 2004.
76.
Martino, S. “The Importance of Breast Cancer Awareness and Forming Support Groups”, presented at the
1st Annual Muslim W omen’s Conference, Los Angeles, CA, July 9, 2005.
77.
Martino, S. ‘Knowledge is Power – Talking About Breast Cancer’, sponsored by The W ellness Community,
W estlake Village, CA , October 17, 2006.
78.
Martino, S. “Be Cancer Free”, Persian American Cancer Institute (PACI) seminar presented at UCLA,
W estwood, CA, June 24, 2007.
79.
Martino, S. “The Patient Active Guide to Living with Advanced Breast Cancer”, sponsored by The W ellness
Community, W estlake Village, CA, June 28, 2007
80.
Martino, S. “Return to W ellness: A New Beginning After Breast Cancer Treatment” Sponsored by The
W ellness Community, W estlake Village, CA, March 24, 2008
81.
Martino, S. “Survivorship: the emotional, psychological, and spiritual aspects of survivorship”, sponsored by
The W ellness Community, presented at the Many Faces of Breast Cancer event, Beverly Hills, CA, May 17,
2008
Silvana Martino, D.O.
Curriculum Vitae
Page 36
82.
Martino, S. “Frankly Speaking About Advanced Breast Cancer”, sponsored by The W ellness Community,
presented at the Frankly Speaking Series, W estlake Village, CA, September 25, 2008
83.
Martino, S. “Breast Cancer Screening”, sponsored by the Persian American Cancer Institute (PACI),
presented at An Afternoon of Awareness, Los Angeles, CA, October 26, 2008.
84.
Martino, S. “Frankly Speaking About Advanced Breast Cancer”, sponsored by The W ellness Community,
presented at the Frankly Speaking Series, W estlake Village, CA, September 24, 2009
85.
Martino, S. “New and Future Therapies for Breast Cancer”, sponsored by The W ellness Community,
W estlake Village, CA, October 21, 2010
86.
Martino, S. “Breast Cancer: Innovations in Diagnosis and Treatment”, sponsored by the Jewish Healing
Center of Los Angeles, October 25, 2010
87.
Martino, S. “ Breast Cancer Update”, sponsored by the Ojai Breast Cancer Survivors, Ojai, CA, September
20, 2011.
88.
Martino, S. “Breast Cancer Update for those with a new diagnosis”, sponsored by the W ellness Community,
W estlake Village, CA, May 21,2012.
Other Scholarly Work (Symposia Organized):
1.
Martino, S. "Chemotherapy of Advanced Disease". American College of Physicians Postgraduate Course,
Medical Oncology-Principles of Patient Management, September 7-10, 1985, W estin Hotel, Detroit, MI.
2.
Martino, S. "LHRH Agonists in the Management of Breast and Prostate Cancer". W ayne State University
School of Medicine. W orkshops in Internal Medicine, January 29, 1986, Harper Hospital, Detroit, MI.
3.
Martino, S. "Health Matters". Channel 56, 1986, 1988, 1990, 1991, Detroit, MI.
4.
Martino, S. Coordinator of Marilyn J. Smith Breast Cancer Prevention Symposium; sponsored by Prentis
Comprehensive Cancer Center of Detroit, October, 1987.
5.
Martino, S. Coordinator of Breast Cancer Prevention Symposium, SW OG, October 1991.
6.
Martino, S. Coordinator of Breast Cancer Update Symposium, W ayne State University, Novi Hilton, Novi, MI,
March 1993.
7.
Martino, S. Co-Chair, ASCO Intergrated Symposia, Her-2 Neu in Breast Cancer, 1998
8.
Martino, S. Co-Chair for Breast Cancer Session, The Fox Chase Cancer Center Investigator’s W orkshop
and Consensus Conference, Lanai, Hawaii, March 4-6, 1999.